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y far the most challenging tasks in assuring the quality and safety of 
pharmaceutical products and the delivery of effective healthcare to 
patients are to detect adulterated, fake, unregulated, and/or poor quality 
medicines, also termed as “falsified medicines”, and to prevent their distribution. 
Falsified medicines are endemic in the global drug supply chain, including traditional 
distribution settings, unregulated sectors, and on the internet. Additionally, substandard 
medicines, which are produced by legitimate manufacturers but fail to meet basic quality 
control tests, pose another risk to patients’ health. At best, these poor quality medicines 
are ineffective; at worst, they result in death. These life-threatening medicines are on the 
rise in both therapeutic and geographic scope, threatening patients’ lives, and profiting 
organized criminal actors involving illicit medicines. Yet, despite these clear threats, 
surveillance is extremely limited, with available data pointing to an increasing global 
health crisis worldwide that is yet to be addressed. 
The aim of this study was to investigate the situation of substandard and falsified 
medicines and the threat they pose to public health. The quality of two lifestyle medicines 
– omeprazole and pioglitazone – was examined in samples collected during surveys in 
Cambodia and Myanmar, and in addition a study of the public health consequences of 
falsified medicines was carried out based on evidence collected from the literature. 
In 2014, quality assessment of omeprazole samples collected from Myanmar showed 
high failure rates in pharmacopoeial tests, especially in dissolution tests. The results 
indicated a high prevalence of substandard omeprazole in the country, and possible causes 
were investigated by means of detailed evaluation of the in vitro dissolution profile, 
B 
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scanning electron microscopy (SEM), and X-ray computed tomography (X-ray CT) 
imaging of the internal structure.  
Further evaluation of the quality of omeprazole purchased from internet sources and 
personally imported into Japan showed variations in the quality of the same product 
from the same manufacturer distributed in developing and developed countries, by 
comparing personal import samples with the products previously collected during the 
surveys in Cambodia and Myanmar.  
Quality assessment of pioglitazone collected in China, Myanmar and purchased from 
internet sources revealed similar quality problems, although most of the pioglitazone 
samples collected from Shanghai, China were satisfactory. In terms of quality, most of 
the unsatisfactory samples failed in the dissolution test. The results of this study result 
suggest that continued monitoring is necessary particularly in Myanmar, Cambodia and 
for personal import medicines.   
To investigate the health consequences of falsified medicines for patients, a study of 
the literature was carried out to identify published papers dealing with this issue. Data 
were collected on the mortality and morbidity of the populations exposed to falsified 
medicines, focusing on the scale of the issue, the geographic extent, the medicines 
affected, and the harm caused. The study indicates that falsified medicines have impacted 
substantially on public health worldwide, and also suggests that developed and 
developing countries are almost equally affected. 
The results of the present studies have enhanced our understanding of the scope of the 
problem of falsified and substandard medicines, and led to several important conclusions. 
The problem of poor and variable drug quality is identified as a major public health 
challenge. It can lead to the therapeutic failure, loss of lives, and loss of trust in the health 
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system. Moreover, online sites selling medicines for personal use pose a substantial risk 
to drug quality. To eliminate the problem of poor drug quality and ensure access of people 
to safe and effective medicines, it will be necessary for all stakeholders to work together 
in undertaking a comprehensive assessment of the quality of medicines accessed locally 
and/or internationally, and also to develop effective regulatory controls to prevent the 
manufacture and distribution of substandard and falsified medicines.
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Chapter 1 
Introduction to the research project 
Chapter 1- Introduction to the Research Project 
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1.1. General introduction 
This thesis and the research reported herein are focused on the issue of ‘falsified and 
substandard medicines’. Specifically, the quality of delayed-release omeprazole capsules 
and pioglitazone tablets collected in several Asian countries was examined, and a review 
of the literature was carried out to investigate the actual health consequences of falsified 
medicines. The aims of this introductory chapter are to introduce the research topic, to 
state the problem that has prompted the research, and to describe the contribution to 
knowledge the research makes. The chapter finishes with an outline of the structure of the 
thesis. 
 
1.2. Research focus, subject issues and interests 
Safety of medicines is essential for patients’ health. But providing safe medicines is 
a complex task, as the circulation of falsified or substandard medications is a global 
problem with a significant impact on the patients who ingest them (Hellstrom, 2011; 
Oshikoya & Senbanjo, 2010). There has been increasing international concern about the 
threat of falsified and substandard medicines (Gautam et al., 2009). The published 
estimates about the global prevalence of falsified medicines range from 1–50%. This 
problem is, however, much more severe in the developing countries; the World Health 
Organization estimates that about 25% of the medicines consumed in developing 
countries may be falsified (Newton et al., 2006; Green, 2006; WHO, 2006). In July, 2013, 
WHO has launched The Global Surveillance and Monitoring System for SSFFC medical 
products in West African region and since then almost 1400 SSFFC medical products 
have been reported (WHO, 2017). 
Chapter 1- Introduction to the Research Project 
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Nevertheless, there are very few published data allowing estimation of the extent of 
the problem and the impact on public health. Only 5–15% of the 191 member states of 
the World Health Organization (WHO) report cases of substandard and falsified drugs. 
Many data have been interpreted uncritically, and some are inaccurate, so it is difficult to 
generalize about the epidemiology of poor quality medicines (Newton et al., 2010; 
Caudron et al., 2008; Newton et al., 2006; WHO, 1999a). 
Non communicable diseases (NCDs) account for about 35 million deaths each year, 
of which 80% occur in low and middle income countries. Most of the conditions that 
cause these deaths can be treated with safe and effective essential medicines. 
Unfortunately access to good quality lifestyle and chronic disease medicines is generally 
poor in many of those countries. In 2009, a southwest China newspaper reported on a 
substandard version of the diabetes drug glibenclamide (also called glyburide) found to 
contain six times the pharmacopeia standard dose (Xiang, 2009). The implementation of 
effective approaches to combating falsified medicines is a matter of great importance for 
any country. However, since the last survey conducted in Myanmar in 1999 
(Wondemagegnehu 1999), little research has been reported, particularly in that country 
(WHO, 1999b). During the past few decades, many pharmaceutical industries and 
distribution channels have flourished globally, which led to an increase in the number of 
products circulating in local and international markets. At the same time, however, the 
presence of falsified and substandard drugs has increased substantially as a result of 
ineffective regulation of the manufacture and trade in pharmaceutical products by both 
exporting and importing countries (Lamy & Liverani, 2015). In these circumstances, 
systemic study is needed in order to obtain independent information about the situation 
Chapter 1- Introduction to the Research Project 
Evaluating the quality of lifetime medicines- results from Asia and the health consequences of 
falsified medicines   Page 4 | 173 
 
of the medical products in the countries and the problem of falsified medicines in order 
to help develop prevention strategies to combat drug falsification. 
1.3. Contribution of the research 
Box 1: Key Messages 
 What is already known in this area of research? 
 Medicine quality is critical to patients’ health - poor quality can lead to 
treatment failure, adverse effects, prolonged illness, and even death. 
 Data about the quality of medicines and the impact of substandard medicines 
on public health is limited, particularly in Myanmar, Cambodia, and for 
medicines purchased via the internet. 
 What does this research add? 
 Provides an up-to-date survey of the quality of lifestyle medicines distributed 
in Myanmar, Cambodia, China, and obtained from internet sources. 
 Provides insight into the prevalence of substandard and variable quality 
medicines circulating in several South Asian countries. 
 Provides an organized summary of published data on the public health 
consequences of falsified medicines. 
 Recommendations 
 The results highlight the need for continuous ongoing surveillance to monitor 
the quality of medicines. 
 Collaborative, comprehensive and harmonized strategies are required for 
addressing variability in drug quality. 
 Local regulatory authorities should be strengthened. 
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The high demand for medicines coupled with limited supply, weak regulatory 
oversight, and limited public awareness all contribute to the trade in falsified and 
substandard medicines. This study provides information about the current status of this 
problem in several countries in Southeast Asia, highlighting potential issues concerning 
regulation of drug distribution and patient safety. The results throw light on how authentic 
manufacturers and the respective regulatory authorities appear to perceive their own roles, 
and how they can contribute to the overall effort to combat the problem of substandard 
and falsified medicines. The findings should be helpful in developing a framework to 
assist decision-makers at national government level in developing suitable regulatory 
strategies. 
One of the key findings of this study is that certain pharmaceutical manufacturers 
appear to be exporting medicines of substandard quality to Cambodia and Myanmar, 
while at the same time, the same manufacturers are providing higher-quality products to 
developed countries. Countries with comparatively weak regulatory bodies may be 
unable to apply stringent criteria in setting quality requirements for products and 
manufacturers. Therefore, product quality is not consistently assured. Thus, there is a 
need for continuous and ongoing monitoring of the quality of medicines from the 
manufacturing process through to distribution, proper storage, and usage. While longer-
term solutions are being developed, it is important to carry out periodic quality testing as 
an evaluation and screening tool to improve current standards. This will help individual 
countries to protect the national drug supply by identifying potential problems, thereby 
enabling them to improve regulation of manufacturers, to prevent poor quality drugs from 
entering the market, to detect them when they do enter the market, and to punish those 
who manufacture and trade them. 
Chapter 1- Introduction to the Research Project 
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1.4. Structure of the thesis 
The report is structured as follows- 
1.4.1. Chapter 2:  Erroneous formulation of delayed-release omeprazole capsules 
alert for importing countries – starts with an introductory part outlining the background 
of the research, statement of the research problem and a succinct literature review. Later 
part discusses the research methodology in details. Results part of this chapter primarily 
presents the summary of the quality test results of delayed-release omeprazole capsules 
collected from Yangon, Myanmar in 2014 and secondarily a detailed investigation of the 
failure of the omeprazole samples from Cambodia in 2010 and Myanmar in 2010. 
Discussion part of this chapter lays out key research findings while emphasizing the 
problem of these substandard medicines, their main causes and research limitations.  
The chapter ends with concluding remarks, including some suggestions on preventive 
measures to stop these poor quality medicines in Cambodia and Myanmar. 
1.4.2. Chapter 3: Quality of omeprazole purchased via the internet and personally 
imported into Japan: Comparison with products sampled in other Asian countries- this 
chapter is a continuation of the previous research work, extended to evaluate the quality 
of omeprazole available in the internet for personal import and to compare the quality 
with previously collected samples from Cambodia and Myanmar. The section mainly 
presents evidence of the quality variation of omeprazole samples from the same 
manufacturers in developed and developing countries. Details of the research findings are 
outlined in the results and discussion section of this section, followed by the conclusion. 
1.4.3. Chapter 4: Public health concerns of substandard antidiabetic medicine: 
Quality estimation of pioglitazone by a cross-sectional survey - discusses the prevalence 
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of substandard pioglitazone available via the internet, as well as from Shanghai, China 
and Mandalay, Myanmar. Findings of this section frame several problems that may hinder 
the access of diabetic patients to pioglitazone of reliable quality, including unregulated 
internet sites that are selling pioglitazone tablets for personal use. The section conveys a 
strong message that when there are unmet needs from internal sources and a weak 
enforcement of regulations. For example, in the case of Myanmar, poor quality medicines 
may enter into the country even through an authorized channel. 
1.4.4. Chapter 5: The health consequences of falsified medicines: A study of the 
published literature - this section presents a review of the published literature data about 
the health effects of falsified medicines on mortality and morbidity, focusing on the scale 
of the issue, the geographic extent, the medicines affected, and the harm caused. 
Published reports are summarized in a long table, arranged according to the economic 
status of the countries involved, region affected, therapeutic category of the medicines, 
number of victims by year, number of incidents by year, and the characteristics of the 
falsified medicines with initial discussion of the definition of substandard and falsified 
medicines, their causes, and potential harmful effect on the patients. 
1.4.5. Chapter 6: General Conclusions and Future Directions - the thesis finishes 
with this chapter outlining the general conclusions of the research, policy implications 
and future directions for limiting the spread of substandard and falsified medicines. 
 
The boxes in each chapter provide a brief overview of the entire chapter highlighting 
the  background, research focus, key findings, strengths, limitations, recommendations, 
and significance of the study.
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Chapter 2 
Erroneous formulation of delayed-release omeprazole 
capsules: Alert for importing countries 
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2.1. Introduction 
There is considerable evidence that the incidence of falsified and substandard 
medicines is increasing, particularly in middle and lower income countries (Almuzaini et 
al., 2013; Newton et al., 2010; Caudron et al., 2008). There have been many well-
established instances of falsified medicines in recent years (Tabernero et al., 2015; 
Khurelbat et al., 2014; Yoshida et al., 2014; Khojah et al., 2013; Kuramoto et al., 2015; 
Wang et al., 2013; Attaran et al., 2012). In addition, substandard medicines, which are 
prepared by legitimate manufacturers but fail to meet pharmacopoeial requirements, also 
constitute an enormous public health problem (Kaur et al., 2008; Onwujekwe et al., 2009; 
WPRO, 2005; Fernandez et al., 2011; WHO, 1999). On-going surveillance seems 
essential. 
The substituted benzimidazoles are a class of anti-secretory compounds that 
suppress gastric acid secretion by inhibition of the H+/K+-ATPase enzyme system at the 
secretory surface of gastric parietal cells (Riedel & Leopold, 2005; Qaisi et al., 2006). 
Among them, omeprazole, 5-methoxy-2-([4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] 
sulfinyl)-1H-benzimidazole, is a basic compound that acts as a proton pump inhibitor, 
and is used in the treatment of acid reflux and heartburn (Hardman et al., 1996). It is acid-
labile, being degraded rapidly in aqueous solution at low pH (Mathew et al., 1995; 
Pilbrant & Cederberg, 1985). Pre-formulation studies confirmed that it is susceptible to 
moisture, heat and acidic solvents (Davidson & McCallum, 1996; Lindberg et al., 1987). 
Therefore, to avoid degradation of omeprazole by acid in the stomach, the drug must be 
enteric-coated (Migoha et al., 2015; Bharate et al., 2010). Consequently, omeprazole 
dosage forms are prepared and marketed in an enteric-coated form that allows the 
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omeprazole core to be specifically released and dissolved in the duodenum (pH > 5) or 
terminal ileum where the pH is about 6.8 to 7.5 (Thoma & Bechtold, 2000). 
Despite increasing attention to the quality of medicines for communicable diseases, 
focus on medicines for non-communicable diseases remains inadequate. In 2010, quality 
test results of omeprazole in Cambodia indicated that more inspection and monitoring of 
medicines for non-communicable diseases is necessary (Yoshida et al., 2014). The 
availability of falsified and substandard medicines in Myanmar was reported by WHO in 
1999 (WHO, 1999), but since then there has been no systematic survey in the country, 
and the current situation is unclear, except for sporadic reports of falsified medicines. 
Based on our experience in Cambodia during 2006-2013 (Yoshida et al., 2014), where we 
encountered various poor quality (mostly substandard) medicines, omeprazole was 
chosen as one of the target medicines for investigation in Myanmar, in consultation with 
the Department of Food and Drug Administration (FDA), Myanmar. Among 65 samples 
of omeprazole capsules collected in Myanmar in 2014, we found high failure rates in 
pharmacopoeial tests, especially dissolution tests. This is broadly consistent with other 
reports of substandard drugs in Cambodia (Khan et al., 2010; Khan et al., 2011). 
The aim of the present study was to establish the cause of the high failure rate of 
omeprazole capsules from Cambodia and Myanmar in dissolution tests by means of 
detailed evaluation of the in-vitro dissolution profile, as well as scanning electron 
microscopy (SEM) and X-ray computed tomography (X-ray CT) examinations. 
Details of the omeprazole samples collected from Cambodia in 2010 and their 
quality test results have been reported by Yoshida et al in BMC Pharmacology and 
Toxicology in 2014. This chapter will primarily focus on the omeprazole samples 
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collected from Myanmar. In the later part, details of the investigation of both Cambodian 
and Myanmar samples will be presented. 
 
 
Box 2: Summary of Chapter 2 
 Research focus 
 Quality investigation of delayed-release omeprazole capsules from Myanmar and 
the cause analysis of the failure of omeprazole samples from Cambodia and 
Myanmar. 
 Key findings 
 Circulation of substandard omeprazole medicine in the countries is identified. 
 Poor enteric coating of the granules and the granules without enteric coating are 
detected. 
 Strengths and limitation of the study 
 Provides important information to the respective regulatory authorities that 
omeprazole medicine was found with high failure rates, especially in the 
dissolution test. 
 Samples were insufficient for detailed examination to confirm the coating material 
used during the manufacture of the enteric coated pellets or if there was inadequate 
coating method. 
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2.2. Methods 
2.2.1. Sample collection 
2.2.1.1. Sampling site and area 
Delayed release omeprazole capsules and tablets were purchased from pharmacies, 
hospitals, and wholesalers located in Yangon, Myanmar during 27 September  to 4 
October, 2014. Sampling sites in Yangon were government hospitals with 200-500 beds, 
private hospitals having pharmacies on their properties and wholesalers identified by 
Myanmar FDA. Community pharmacies and clinical pharmacies in clinics were visited 
along the streets to hospitals. 
2.2.1.2. Sample size and collected amount per sample 
At least 40 dosage units of each medicine were to be collected. The same sample 
code was assigned to each sample of the same product with the same batch number 
collected at the same shop at the same time. For tablets and capsules, 100 dosage units 
were collected in principle. Forty dosage units were kept by the Department of Food and 
Drug Administration (FDA), Ministry of Health, Myanmar for confirmation testing in the 
event of failure at Kanazawa University, and the rest were sent to Kanazawa University 
for authenticity investigation and analysis. 
2.2.1.3. Sampling procedure 
Two teams were assigned for sampling. Each team consisted of a local supervisor, a 
local assistant, and one or two researcher(s) from Japan. A sampling form containing 
observed information of the outlet and product information was completed by samplers 
just after the purchase of each sample (Appendix 1). Samples were sealed in a plastic bag 
and a serial number label was attached immediately after the collection. Vehicles were 
air-conditioned. 
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2.2.2. Observation test 
For all the samples the observation inspection was made with the help of the “Tool 
for Visual Inspection of Medicines” produced by the International Council of Nurses in 
partnership with the United States Pharmacopoeia (USP) and modified by the Military 
and Emergency Pharmacists Section of FIP (FIP, 2014) (Appendix 2). 
2.2.3. Authenticity investigation 
Authenticity investigation was performed according to the modified WHO method 
(WHO, 1999). The procedure was to ask the manufacturers stated on the label of the 
product about authenticity and also to ask the Medicines Regulatory Authorities (MRA) 
of manufacturing countries about the legitimacy of the products and manufacturers. 
Questionnaires, including pictures of the sample and if requested some tablets, were sent 
to the manufacturer and MRA for evaluation of authenticity (Appendix 3, 4, 5, & 6). 
Registration numbers in Myanmar were verified by the FDA, Ministry of Health and 
Sports, Myanmar (Appendix 7 & 8). 
2.2.1. Analytical procedure 
2.2.1.1. Materials and reagents 
United States Pharmacopeia (USP) reference standard omeprazole was procured 
from USP Convention. Authentic omeprazole standard capsules (Losec) were provided 
by AstraZeneca. Lansoprazole (internal standard) was from Sigma Aldrich (India).  
NaH2PO4.2H2O, Na2HPO4, Na3PO4, KH2PO4 and other chemicals of reagent grade were 
purchased from Nacalai Tesque Inc. (Kyoto, Japan). Distilled water was used for the 
preparation of HPLC eluents. 
The investigational samples consisted of 154 samples of hard gelatin capsules 
containing 20 mg of omeprazole in enteric-coated pellets and two tablet samples 
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purchased from different drug stores in Cambodia in 2010 and Myanmar in 2014. These 
samples were from 53 different manufacturers in seven countries. Samples were stored 
below 25 ºC after collecting and all the quality analysis of the samples was finished before 
expiration date of the samples. After quality-testing as required by the indicated 
pharmacopoeia, we selected five samples for further investigation based on the gravity of 
their failure in the dissolution test. 
2.2.2. HPLC determination of omeprazole 
HPLC was run on a Phenomenex Gemini NX C18 column (150 x 4.6 mm), with a 
Prominence HPLC Photo Diode Array Detector (SPD-20A/20AV Series; Shimadzu, 
Kyoto, Japan). The temperature of the column oven was set to 25 °C. Elution buffer was 
prepared by dissolving 1.17 g NaH2PO4.2H2O and 1.06 g Na2HPO4 in 1000 ml of water; 
the pH was adjusted to 6.8. The column was eluted with a mixture of  phosphate buffer 
and acetonitrile (60:40) at a flow rate of 0.5 ml/min. Detection wavelength and injection 
volume were 302 nm and 10 μL, respectively for British Pharmacopoeia (BP) samples. 
For USP samples, the flow rate was 1 ml/min, detection wavelength was 280 nm, and 
injection volume was 10 μL. 
2.2.3. Omeprazole identification, quantity and content uniformity tests 
Identification, Quantity and content uniformity tests of omeprazole samples were 
carried out according to the modified method of BP 2010 and 2015 (BP, 2010; BP, 2015) 
or USP 34 and 37 (USP, 2011, USP, 2014) as indicated in the package insert or on the 
outer package of each sample. For the identification test, a chromatogram of the sample 
was compared with that of reference standard omeprazole. The retention time of the 
principal peak in the sample chromatograms was similar to that of the peak of standard 
omeprazole. Standard solutions were prepared by dissolving accurately weighed 
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quantities of omeprazole (reference standard) and lansoprazole (internal standard) in the 
diluent to obtain solutions with concentrations of 0.2 mg/ml and 0.1 mg/ml, respectively. 
From these stock solutions, 5 diluted omeprazole solutions (0.2, 0.15, 0.1, 0.05 and 0.025 
mg/ml) were prepared. The relationship between the peak area and concentration of each 
reference standard was linear within the range of 25-200% of the active ingredient (r2 = 




Figure 2.1: Calibration curve of omeprazole reference standard 
2.2.3.1. Acceptance criteria 
In the pharmacopoeial test, quantity and content uniformity acceptance criteria of 
the delayed release omeprazole capsules were as follows- 
 Quantity test 
 BP: Omeprazole tablets/capsules contain the equivalent of not less than 95.0% 
and not more than 105.0% of the labeled amounts of omeprazole. 
y = 350.95932 x - 0.02712 
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 USP: Omeprazole tablets/capsules contain the equivalent of not less than 90.0% 
and not more than 110.0% of the labeled amounts of omeprazole. 
 Content Uniformity test 
Calculation of acceptance value (AV); calculate the acceptance value by the formula- 
AV= |M-x̄ | + KS where, M: reference value; x̄: mean of individual contents; K: 
acceptability constant, K=2.4 when the number of unit is 10, and the K=2 when the 
number of unit is 30; S: standard deviation of the sample. 10 units were assayed 
individually, the requirements for dosage uniformity are met if the acceptance value of 
the first 10 dosage units was less than or equal to 15 for the first stage. In 2nd stage AV of 
30 units ≤ 15 (1st stage 10+2nd stage 20 more units). No individual content of any dosage 
unit is less than 0.75M % or more than 1.25M% (M=Reference value). 
2.2.4. Omeprazole dissolution test and examination of dissolution profile 
Dissolution test was performed according to the BP or USP as indicated by the 
sample products. BP Samples were exposed to 700 ml phosphate buffer, pH 4.5, for 45 
minutes in acid stage and 900 ml phosphate buffer, pH 6.8 for 45 minutes in buffer stage 
(BP, 2010; BP, 2015). USP samples were exposed to 500 ml of 0.1 N HCl for 2 hours in 
acid stage and 900 ml of phosphate buffer, pH 6.8 for 30 minutes in buffer stage (USP, 
2011, USP, 2014). The dissolution test was conducted with a NTR-VS 6P dissolution 
apparatus (Toyama Sangyo Co. Ltd., Osaka, Japan). Drug release studies were carried out 
by paddle method. The paddle was set to rotate at 100 rpm and the temperature was 
maintained at 37 ± 0.5 °C.  
To examine the dissolution profile, 3 capsules were used. Since all the failed samples 
were BP samples, in the investigation with the acid stage, test samples were exposed to 
700 ml phosphate buffer, pH 4.5, for 45 minutes. After 45 minutes, a 5 ml aliquot was 
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withdrawn from each vessel for quantification by HPLC.  Then 200 ml of phosphate 
buffer, pH 7.6, was added to adjust the final pH to 6.8 (buffer stage). In this stage, 5 ml 
aliquots were withdrawn from each dissolution vessel at 5, 15, 30, 45, and 60 minutes for 
quantification by HPLC. In the investigation without the acid stage, samples were 
exposed to the buffer stage directly without the previous acid stage, and samples were 
collected in the same manner as described above. 
2.2.4.1. Acceptance criteria 
In the pharmacopoeial test, quantity and content uniformity acceptance criteria of 
the delayed release omeprazole capsules were as follows- 
 Dissolution test 
 BP 
Acid Stage (45 minutes)- Stage 1: Each unit of 6 capsules is not more than 10%; 
Stage 2: Average value of 12 units not more than 10% and no unit is greater than 25%; 
Stage 3: Average value of 24 units not more than 10% and no unit is greater than 25% 
Buffer stage (45 minute)- Stage 1: no unit is less than Q+5% (Q=65); Stage 2: 
Average value of 12 units is more than or equal to Q (Q=65) and no unit is less than Q-
15%; Stage 3: Average value of 24 units more than or equal to Q (Q=65), not more than 
2 units is less than Q-15% and no unit is less than Q-25% 
 USP 
Acid Stage (120 minutes)- Stage 1: Each unit of 6 capsules is not more than 15%; 
Stage 2: Average value of 12 units not more than 20% and no unit is greater than 35%; 
Stage 3: Average value of 24 units not more than 20% and no unit is greater than 45% 
Buffer stage (30 minutes)- Stage 1: no unit is less than Q+5% (Q=75); Stage 2: 
Average value of 12 units is more than or equal to Q (Q=75) and no unit is less than Q-
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15%; Stage 3: Average value of 24 units more than or equal to Q (Q=75), not more than 
2 units is less than Q-15% and no unit is less than Q-25%. 
2.2.5. Scanning electron microscopy 
Surface morphology of omeprazole granules was characterized by means of 
scanning electron microscopy on a Hitachi S-3400 instrument equipped with a Hitachi E-
1010 ion sputter device. A few omeprazole granules were removed from the capsule shell, 
mounted on a stub of metal with adhesive, coated with platinum, and observed.  
2.2.6. X-Ray computed tomography 
X-Ray CT of the samples was conducted using an inspeXio SMX-100CT 
(Shimadzu) equipped with a sealed tube type micro focus X-ray generator with a 
maximum output of 100 kV, and a high-sensitivity image intensifier. The sample granules 
were positioned between the X-ray generator and the X-ray detector, and X-ray 
fluoroscopic data was collected from every angle by rotating the sample through 360º. 
Finally, computed tomographic images (CT images) were calculated from the obtained 
data.
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2.2.7. Statistical analysis 
Statistical analyses were performed using Microsoft Excel and SPSS 19.0.0 (IBM 
SPSS Inc. Chicago, IL, USA). Statistical differences between the experimental groups 
were analyzed by Student’s t test. Statistical significance was evaluated at the 5% level. 
 
2.3. Results 
In Myanmar, 2014, a total of 65 omeprazole samples from 21 different 
manufacturers of four different countries were collected. Details of the samples are 
outlines in Table 2.1. 
 
Table 2.1: Outline of the omeprazole samples collected from Yangon, Myanmar in 
2014 
 
Country Shop category 
No. of samples 
n (%) 
Country of manufacturer 
Domestic n (%) Imported n (%) 
Myanmar, 2014 
(n = 65) 
Pharmacy 35 (53.8) 
0 (0) 65 (100) Hospital 26 (40) 
Wholesaler 4 (6.2) 
 
2.3.1. Observation result 
2.3.1.1 Pharmaceutical shops 
All shops were equipped with awnings to protect medicines from direct sunlight. 
The average temperature in shops without air-conditioning was 30.8±2.2 0C while 
28.6±2.6 0C with air-conditioning (t-test, p<0.01). An average humidity in shops without 
air-conditioning was 69.3±8.7 % while 67.90±12.4 % (t-test, n.s.). At some shops, a 
motorbike, a dog, a cat or a person eating was observed in the dispensing area. 
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2.3.1.2. Sample observation 
As per the result, two of the sample did not contain any box. Each Strip was found 
without any type of packaging. Most of the container did not contain tamper proof sealing. 
Manufacturer name was not found in case of two samples. Among 65 sample collected, 
14 samples did not have either any logo or hologram. Product insert was not found in 9 
samples. Mixed colored granules were also observed in a sample the result of which will 
be discussed separately in the later part. 
 
2.3.2. Authenticity investigation 
2.3.2.1.  Verification of origin/source of the products 
According to the questionnaire sent to the manufacturers, 2 manufacturers have 
replied by 20 May 2015. Two samples out of 65 (3.4%) were confirmed as genuine 
products and no falsified medicines was reported (Table 2.2). Most manufacturers had a 
contact e-mail address, but in many cases, there was no reply even after a reminder e-
mail. 
 
2.3.2.1. Legitimacy of the manufacturers and products 
Questionnaires were sent to 5 MRAs in manufacturing countries (Bangladesh, India, 
Myanmar, Singapore, and Thailand) by e-mail in December 2014. Unfortunately, no 
response was obtained from the any of the MRAs except from Myanmar. All 
manufacturers and samples of omeprazole (100 %) were found to be registered to 
Myanmar FDA (Table 2.2). 
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Reply on samples 
(number of samples) 
Authentic 
Yes No Unknown 
Authenticity of 
the product 
Manufacturer 2 (21) 4 (65) 2  2 




0 (4) 0 (65)    








Table 2.3: Quality test result of omeprazole from Cambodia in 2010 and Myanmar 
in 2014 
 
Country Quality tests 
Pass Fail Pending1 
n (%) n (%) n (%) 
Cambodia, 2010 
(Yoshida et al, 2010) 
Quantity 54 (59.3) 22 (24.2) 15 (16.5) 
Content Uniformity 31 (34.1) 14 (15.4) 46 (50.5) 
Dissolution 42 (46.2) 45 (49.4) 4 (4.4) 
 Quantity 42 (64.6) 23 (35.4) 0 (0) 
Myanmar, 2014 Content Uniformity 56 (86.2) 9 (13.8) 0 (0) 
 Dissolution 48 (73.8) 17 (26.2) 0 (0) 
 
                                                     
1 Insufficient material was available for full testing 
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Among the 156 omeprazole samples collected, 45 (28.8%) were unacceptable in the 
quantity test, while 23 (14.7%) were unacceptable in the content uniformity test. In the 
dissolution test, 90 samples (57.7%) were acceptable and 62 (39.7%) were unacceptable 
Summary of the quality test results is shown in Table 2.3 and the details are presented in 
Appendix 9-13. 
 
2.3.2. Dissolution profile: Effect of the acid stage on drug release 
Fig 2.2(A) shows the percent of omeprazole released in buffer from a standard 
sample (Losec) with and without the acid stage; in this case, the enteric coating of the 
granules retained its integrity in the acid stage, as expected, and the percent release of 
omeprazole without the acid stage was not much different from the percent release of 
omeprazole with the acid stage. Fig 2.2(B), 2.2(C), & 2.2(D) show the percent of drug 
released from the omeprazole granules of one Cambodian sample and two Myanmar 
samples respectively. In these cases, the pattern of drug release in buffer without the acid 
stage was significantly higher than that with the acid stage, suggesting that the enteric 
coating of the failed samples was not fully effective. 
 
2.3.3. Acid degradation of omeprazole 
Typical chromatograms of reference standard omeprazole, standard omeprazole 
sample, a passed omeprazole sample and a failed omeprazole sample are shown in Fig 
2.3. The failed sample showed peaks indicating that degradation had occurred. To confirm 
this, reference standard (pure) omeprazole was exposed to acid (pH 4.5) and aliquots were 
withdrawn for HPLC analysis at 0, 10, 30, and 45 minutes. 
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Figure 2.2: Dissolution profiles (percent release) of omeprazole in buffer stage with 
and without acid stage. A) The standard sample; B) failed B-040 omeprazole sample 
from Cambodia; C) failed B-110 omeprazole sample from Myanmar; and D) failed A-
078 omeprazole sample from Myanmar. Each value represents mean ± SD of three 
capsules except for (B) where n = 1. Significant differences were evaluated (**p < 0.01) 
comparing percent dissolution of the capsules in with and without acid stage at each time 
point using student’s t-test. For the dissolution profile of Cambodian sample only one 
capsule was used in each stage, the result of which was not available for statistical 
comparison 
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As shown in Fig 2.4, peaks of degradation products increased time-dependently, and 
the time course of remaining omeprazole is shown in Fig 2.5. These results are consistent 
with the conclusion that the failed omeprazole samples lacked effective enteric coating. 
 
 
Figure 2.3: HPLC chromatogram of omeprazole samples in acid resistance stage. A) 
Omeprazole reference standard; B) standard omeprazole sample; C) passed omeprazole 
sample; and D) failed omeprazole sample 
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Figure 2.4: Chromatograms of pure omeprazole in acid at different time points. A) 
0 min; B) 15 min; C) 30 min; and D) 45 min 
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Figure 2.5: Time course of degradation of pure omeprazole in acid 
 
2.3.4. Variability of granules in samples 
Considerable variability related to the formulation or manufacturing process of 
omeprazole has been suggested in Cambodian samples (Yoshida et al., 2014), and we 
found similar variation in some Myanmar samples. The shape of the granules ranged from 
spherical to irregular, and different-colored granules were seen, as illustrated in Fig 2.6.  
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Figure 2.6: Difference in the color of granules in a capsule (sample A-078). A) Mixed 
granules found after opening the capsule shells; B) separated white granules; C) grey 
granules; D) yellow granules; and E) particles found in the capsule which were not 
granules 
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In the same capsule, there were some particles which could not be detected as 
granules. We isolated white, yellow, and grey granules, and quantified them individually. 
Irregular particles were not quantified as the amount of the particles was not enough for 
quantity test. The omeprazole contents in the white, grey and yellow granules were 64.1 
± 0.2, 61.4 ± 0.5 and 42.7 ± 1.7 mg (mean ± SD) per 267.8 mg of granules (average 
weight of six granules). The amount of omeprazole content in each 3 different granules is 
shown in the Table 2.4. 
 
Table 2.4: Different amount of omeprazole content in the different colored 
granules in the sample A-078. Same weight (average weight of 6 capsule) was taken for 
all three colored granules 
 
Granule type White granules Grey granules Yellow granules 
Weight 267.8 mg 267.8 mg 267.8 mg 
QTY±SD 64.1±0.2 61.4 ± 0.5 42.7±1.7 
 
2.3.5. Examination of granules by scanning electron microscopy 
Representative SEM images are shown in Fig 2.7. Compared with the standard 
sample (A), granules from failed omeprazole samples collected in Cambodia in 2010 
showed cracks in the enteric coating, along with the broken pellets. These were mixed 
with the regular granules in the capsule. 
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Figure 2.7: SEM images of cracked and fractured pellets found in two representative 
Cambodian samples. A) Standard sample; B) and C) two different granules of sample 
A-063; and D) Sample A-108 
 
2.3.6. Examination of granules by X-ray computed tomography 
To confirm the absence of functional enteric coating, we performed X-ray CT on 
selected samples that failed severely in the dissolution test and conducted a comparative 
study of the standard sample and failed samples. Fig 2.8 shows two different granules 
taken from the same capsule in a sample collected in Cambodia in 2010. One granule 
shows an apparently intact coating (Fig 2.8A), while the other (Fig 2.8B) has essentially 
no coating at all. Similar results were seen in failed samples from Myanmar, which 
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contained non-uniform granules, incomplete granules and granules with holes. Fig 2.9 




Figure 2.8: X-Ray CT images of granules found in sample B-040 collected in 
Cambodia in 2010. Note the presence of an apparently intact enteric-coated layer in (A) 
and the absence of an enteric-coated layer in (B) 
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Figure 2.9:  X-Ray CT images of granules found in sample A-078 collected in 
Myanmar in 2014. A) Standard sample; B) regular granule with apparently intact coating 
(white granule 1); C) irregular granule with hole (white granule 2); and D) yellow granule 
with incomplete coating 
 
2.4. Discussion 
Our findings for samples collected in Myanmar in 2014 indicate that the incidence 
and condition of substandard omeprazole medicines in Myanmar are quite similar to those 
in Cambodia. Yoshida et al. found that 45 out of 91 omeprazole samples collected in 
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Cambodia in 2010 (49.5%) were failed in the dissolution test (Table 2.3) (Yoshida et al., 
2014). Among the Myanmar samples, 23 (35.4%) failed the quantity test, although the 
extent of failure was generally marginal. A few failed due to over-content. Moreover, 
significant differences were observed in the quality test, where some brands passed in 
most cases, while others were consistently substandard. It was particularly noteworthy 
that the products of certain manufacturers failed consistently. 
In the present work, our prime concern was the failures in dissolution tests. Among 
the 17 (26.2%) failed samples from Myanmar, all failed in the buffer stage and 11 failed 
in both the acid and buffer stages. A key issue appeared to be that the coating of the 
granules did not provide good control of the drug release, so that rapid disintegration and 
dissolution occurred in the acid stage of the test, resulting in exposure of omeprazole to 
acid degradation (Qaisi et al., 2006; Mathew et al., 1995; Davidson & McCallum., 1996; 
Jee et al., 1992). Indeed, an HPLC analysis showed that degradation of omeprazole in the 
granules of failed samples during the acid stage was similar to that of pure omeprazole 
(Fig 2.3 & 2.4), confirming that the enteric coating was ineffective. 
This conclusion was further supported by SEM images (Fig 2.7), which revealed 
fractured pellets and pellets with incomplete coating, together with pellets with apparently 
intact coating. Macroscopically, a sample from Cambodia contained two different types 
of granules in a single capsule, and the X-ray CT images showed that one type of granule 
lacked enteric coating (Fig 2.8B). Similar results were found in a sample from Myanmar, 
which appeared to contain three different types of granules (Fig 2.6). The X-ray CT 
images revealed that the coating of some granules was incomplete and some granules 
contained holes (Fig 2.9). Thus, there was marked inconsistency among omeprazole 
granules in capsules, and this suggests that at least some 
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manufacturers were using inadequate enteric coating technology or conditions. However, 
we were unable to confirm this with the manufacturers. Substandard medicines are a 
serious public health issue. In the case of omeprazole, substandard samples without 
enteric coating or with incomplete enteric coating will degrade rapidly in the acidic 
environment of the stomach after oral administration, and this may result in treatment 
failure. 
It should be noted that in some cases the size of our samples was insufficient for 
detailed examination, and this represents a weakness of our study, in that we could not 
fully assess the actual extent of quality failure in our analysis. Another limitation is that; 
we could not confirm the coating material used during the manufacture of the enteric 
coated pellets or if there was inadequate coating method (e.g. inadequate equipment or 
inadequate coating parameters) as the response to the questionnaire from the 
manufacturers was minimum. Therefore, further investigation is needed to establish 
precisely the scale of the problem of substandard medicines in Myanmar and Cambodia. 
In addition, action, including regulatory measures, should be initiated to prevent the 




Samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar in 
2014 showed high failure rates in pharmacopoeial testing, especially in the dissolution 
test. In-vitro dissolution profiling, scanning electron microscopy and X-ray computed 
tomography showed that failed samples contained granules with ineffective (cracked or 
incomplete) or absent enteric coating. This would result in premature dissolution in acidic 
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conditions after oral administration, and could result in treatment failure. This situation is 
a potentially serious public health issue that needs to be addressed by regulatory 
authorities in Cambodia and Myanmar, possibly through legal measures and collaborative 
initiatives with manufacturers.
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3.1. Introduction 
One of the major challenges to global health is the growing burden of non-
communicable diseases (NCDs), which are predicted by the World Health Organization 
(WHO) to be the leading cause of death and disabilities worldwide by 2030 (Bollyky, 
2013; WHO, 2010; WHO, 2014; WHO, 2005). Indeed, the prevalence of NCDs is 
estimated to be up to 27.8% in North America and 25.9% in Europe. Among the NCDs, 
gastroesophageal reflux disease (GERD) is one of the most common (El-Serag et al., 
2014; Tack et al., 2012; Remais et al., 2012). It is often treated with a proton pump 
inhibitor, such as omeprazole, which is available as an over-the-counter (OTC) drug in 
many countries, but is a prescription drug in Japan. However, the recent rise in e-
commerce and the proliferation of illicit online pharmacies has enabled patients in Japan 
to obtain many drugs directly, with or without a prescription (Venhuis et al., 2014; 
Mackey & Nayyar., 2016; Fittler et al., 2013; Nielsen & Barratt., 2009). Indeed, 
LegitScript’s annual report in 2016 estimated that about 3,000 websites, or 10% of the 
world’s rogue internet pharmacies, take Japan as their primary target, making it the 
second-largest market for illegal online drug sellers (Mackey & Nayyar., 2016; Fittler et 
al., 2013; LegitScript, 2016; Siva, 2009; Monteith et al., 2016). This is an important issue 
because of the potential for proliferation of substandard and falsified medicines.  
Substandard medicines may be prepared by legitimate manufacturers, who fail to 
meet pharmacopoeial standards due to accidental breaches of good manufacturing 
practice, or may be a consequence of inadequate storage conditions in the distribution 
chain (Onwujekwe et al., 2009; WPRO, 2005; Fernandez et al., 2011). On the other hand, 
falsified medicines are produced and sold with deliberate misrepresentation of their origin, 
authenticity or effectiveness. These products circulate because of the constant demand for 
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medicines and weaknesses in national regulatory systems (Buckley & Gostin, 2013). The 
term falsified medicine is often broadly used to cover substandard, spurious, falsely 
labeled, falsified and counterfeit (SSFFC) medicinal products. 
According to PSI (Pharmaceutical Security Institute) data, the prevalence of falsified 
medicines has increased drastically between 2002 and 2012 (Attaran et al., 2012; PSI, 
2015). Even so, the reported prevalence would likely have been higher if resource-poor 
countries had adequate follow-up and reporting systems (Attaran et al., 2012). Also, drug-
regulatory authorities in countries with adequate law enforcement and pharmaceutical 
companies conducting oversight do not necessarily release their records publicly 
(Buckley & Gostin, 2013; Attaran et al., 2012; WHO, 1999; WHO, 2017). The 
seriousness of the situation is illustrated by the fact that in 2010, about 67% of omeprazole 
samples collected from Cambodia proved to be failed in quality tests (about 98 % of these 
samples had been imported from various countries) (Yoshida et al., 2010). Also, about 
50% of omeprazole samples from Myanmar proved to be failed in quality tests in 2014 
(100% of them were imported) (Rahman et al., 2017).  
In this context, the present investigation was undertaken with the primary objective 
of evaluating the quality of omeprazole ordered via the internet and personally imported 
into Japan. We also examined whether there was a quality difference between these 
personally imported products and products previously collected in other Asian countries 
and labeled as being manufactured by the same companies.
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3.2.1. Source selection and collection of samples 
The Google Japan search engine was used to search for pharmacies offering 
omeprazole product was included in this study. The searches were performed during the  
Box 3: Summary of Chapter 3 
 Research focus 
 Evaluation of the quality of omeprazole purchased via the internet and personally 
imported into Japan. 
 Comparing the quality of these samples with that of the same products from the 
same manufacturers previously collected in surveys in two other Asian countries. 
 Key findings 
 Omeprazole formulations are readily available online with or without a 
prescription. 
 Quality of personally imported omeprazole from online sources was satisfactory. 
 Omeprazole from the same manufacturers in developing and developed countries 
had variable quality. 
 Strengths and limitation of the study 
 Present the research-based evidence of the quality variation of omeprazole samples 
by the same manufacturers for developed and developing countries, highlighting 
the need for better cooperation from manufacturers and regulatory authorities. 
 Relatively small number of the samples and sampling sites 
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19th August to 12th September 2013. The search terms used were  ‘オメプラゾール 
and 個人輸入’ for Japanese sites and ‘Omeprazole and personal import’ for English sites. 
Among the hits, pharmacies offering omeprazole 20 mg tablets or capsules were selected. 
Samples were purchased from them online and personally imported into Japan during 
August to September 2013. 
3.2.2. Observation test 
Each sample was assigned a code upon receipt. Details of the packaging condition, 
label information, product name, dosage form, dosage strength, manufacturers’ name and 
address, batch number, manufacturing and expiry dates, etc., were noted and evaluated 
according to the FIP (International Pharmaceutical Federation) checklist (Appendix 2) 
(FIP, 2017). 
3.2.3. Authenticity investigation 
The methodology of the authenticity investigation and registration verification was 
adopted from WHO (Yoshida et al., 2015; Khan et al., 2012; WHO, 2010). A 
questionnaire accompanied by a photograph of the sample was sent the relevant 
manufacturing company for confirmation of authenticity (Appendix 3 & 4). Printed 
information from the product package was also verified from the manufacturers’ website.  
The regulatory authorities in the countries of origin and distribution were also contacted 
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3.2.4. Quality analysis 
3.2.4.1. Materials 
Reference standard omeprazole was procured from USP Pharmacopeial Convention 
and omeprazole standard capsules were a gift from AstraZeneca. Lansoprazole as an 
internal standard was purchased from Sigma-Aldrich (India). NaH2PO4.2H2O, Na2HPO4, 
Na3PO4, KH2PO4 and other chemicals of reagent grade were purchased from Nacalai 
Tesque Inc. (Kyoto, Japan). Distilled water was used for the preparation of HPLC eluents. 
3.2.4.2. Analytical procedure 
Quality analysis (identification, quantity, content uniformity, and dissolution test) 
was done according to the pharmacopoeia indicated in the package insert or on the outer 
package of each sample (BP, 2010; BP, 2015; USP, 2011; USP, 2014; JP, 2012; IP, 2014). 
A high-performance liquid chromatograph (SPD-20A/20AV Series; Shimadzu, Kyoto, 
Japan) with a photo diode array detector was used. 
The dissolution test was performed with an NTR-VS 6P dissolution apparatus 
(Toyama Sangyo Co. Ltd., Osaka, Japan). Drug release studies were carried out by the 
paddle method. The paddle was set to rotate at 100 rpm and the temperature was 
maintained at 37 ±0.5 ºC. 
Standard solutions were prepared by dissolving accurately weighed quantities of 
omeprazole (reference standard) and lansoprazole (internal standard) in the diluent to 
obtain solutions with concentrations of 0.2 mg/mL and 0.1 mg/mL, respectively. From 
these stock solutions, 5 diluted omeprazole solutions (0.2, 0.15, 0.1, 0.05 and 0.025 
mg/ml) were prepared. The relationship between the peak area and concentration was 
linear within the range of 25–200% of the active ingredient (r2 = 0.999–1.000), and the 
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quality test was performed within that range. Acceptance criteria of the sample were set 
according to the respective pharmacopoeia requirements. 
3.2.5. Raman spectroscopic analysis 
Raman spectroscopic analysis was done using Inspector 500 (SciAps Inc., USA) 
equipped with higher-wavelength Raman excitation, consisting of a 300 mW 1030 nm  
Class III B laser and a cooled Type III-IV semiconductor detector array (spectral range 
100-2500 cm-1). The concordance rate was calculated by using the NuSpec Pro software 
(SciAps Inc., USA). Granules of each sample were placed in front of the laser source (3 
times each for 3 different granules) and the Raman spectral data were recorded and 
compared with those of the standard sample. 
3.2.6. Data analysis 
Data analysis was performed using Microsoft Excel 2010 and Principal component 
analysis (PCA) of Raman spectra was analyzed using the Unscrambler (Camo Software, 
Oslo, Norway). PCA was performed on smoothed spectra to determine potential grouping 




3.3.1. Online sites 
A total of 31 sites selling omeprazole were found. Among them, 13 sites were in 
Japanese and the other 18 sites were in English. Among the 13 Japanese-language sites, 
none asked for a prescription, and 26 samples of 16 different products were purchased 
from these sites. Among the 18 English sites, 16 asked for a prescription and the other 
two sold omeprazole as an OTC product. Two additional samples of the same product 
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were purchased from these two sites. Among the 31 sites, two did not give any physical 
address, two sites had no contact phone number, and 6 sites did not recommend 
consultation with a physician or pharmacist. 
3.3.2. Sample observation 
A total of 28 samples were purchased, which were labeled as being from 17 different 
manufacturers in 6 countries, and were distributed from 7 different countries. 
Examination according to the FIP checklist revealed that one sample had no 
manufacturer’s name or batch number. One sample was different from the ordered sample 
advertised on the site. One sample was found with loose granules outside the capsule shell, 
and one sample was found with a cracked capsule shell (Fig 3.1A and B). 
 
  
Figure 3.1: Loose granules outside the capsule shell (a) and defective capsule shell of 
sample (b) 
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3.3.3. Authenticity investigation 
A questionnaire was sent to each manufacturer for product authenticity and legality 
investigation, as well as to the manufacturing country and country of distribution. Among 
the 17 manufacturers, no response was received from any manufacturer. In legality 
investigation, 2 manufacturing countries among 6 replied that 8 samples were legal. 
Among the 7 distribution countries (11 distributors), replies were received from 3 
countries, and 1 distributor was found to be licensed. 
3.3.4. Quality test result 
Among the total of 28 samples collected, six were tablets and 22 were capsules. For 
the identification test, the chromatogram of a sample was compared with that of the 
reference standard omeprazole. The retention time of the principal peak in all the sample 
chromatograms was similar to that of the peak of standard omeprazole, and the UV 
spectra of the standard and samples were identical. The results of the quality tests are 
summarized in Table 3.1. 
 
Table 3.1: Quality test results of omeprazole personally imported into Japan 
 














No. of samples (%) 26 (92.9) 2 (7.1) 26 (92.9) 1 (3.6)2 28 (100) 0 
 
 
                                                     
2 2nd stage test was not done for one sample because the number of tablets was insufficient. 
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3.3.5. Quality difference among products from the same manufacturers in 
different market segments 
In Cambodia 2010, a study conducted by Yoshida et al. (Yoshida et al., 2014) found 
serious quality deficiencies, especially in the dissolution test, in omeprazole samples from 
some manufacturers. Similar results were reported from Myanmar in 2014 by Rahman et 
al. (Rahman et al., 2017). The samples from Cambodia and Myanmar had mainly failed 
the dissolution test in the acid stage, indicating ineffective enteric coating to protect 
omeprazole in the core. 
 






















Personal import 1 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 
Cambodia 2010 4 1 (25) 3 (75) 1 (25) 3 (75) 4 (100) 0 (0) 
Myanmar 2014 18 14 (77.8) 4 (22.2) 18 (100) 0 (0) 10 (55.6) 8 (44.4) 
Manufacturer Y4 
Personal import 3 3 (100) 0 (0) 3 (100) 0 (0) 3 (100) 0 (0) 
Cambodia 2010 5 4 (80) 1 (20) 3 (60) 2 (40) 0 (0) 5 (100) 
Myanmar 2014 4 3 (75) 1 (25) 4 (100) 0 (0) 0 (0) 4 (100) 
 
                                                     
3 Pass and fail percentage of samples were calculated from the total number of samples from each 
sampling site. 
4 Pass and fail percentage of samples were calculated from the total number of samples from each 
sampling site. 
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Interestingly, manufacturers of those poor quality products had also produced some 
of the samples obtained in our current study, which successfully passed quality tests. 
Quality test results of omeprazole samples from two of those manufacturers (X & Y) 
collected previously from Cambodia and Myanmar are presented in Table 3.2 along with 
the results of personal import samples. 
 
3.3.6. Raman spectroscopic analysis 
Raman spectroscopy was applied to compare the products from the same 
manufacturers, collected at different sites. In the case of manufacturer X, the similarity of 
the Cambodian product to the personal import product was 68%, and that of the Myanmar 
product to the personal import was 62%; in contrast, the similarity of the Cambodian and 
Myanmar products was 94% (Fig 3.2a, b, & c). In the case of manufacturer Y, the 
similarity of the Cambodian product to the personal import product was 92%, and that of 
the Myanmar product to the personal import was 94%, whereas the similarity of the 
Cambodian and Myanmar products was 98% (Fig 3.3a, b, & c). For comparison, Raman 
spectra of the respective samples from manufacturer X & Y was further evaluated by PCA. 
The PCA results obtained with Raman spectra demonstrated the similar variation to 
clearly distinguish the samples from the same manufacturers. PCA results for the 
derivative Raman spectra are presented in Fig 3.4 and 3.5 for manufacturer X and Y, 
respectively. 
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Figure 3.2: Raman spectroscopy of samples from manufacturer X. a) Personal import 
and Myanmar products, b) Cambodian and personal import products, c) Cambodian and 
Myanmar products 
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Figure 3.3: Raman spectroscopy of products from manufacturer Y. a) Personal import 
and Myanmar products, b) Cambodian and personal import products, c) Myanmar and 
Cambodian products 
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Figure 3.4: PCA score plot for Cambodia, Myanmar, and personal import samples 





Figure 3.5: PCA score plot for Cambodia, Myanmar, and personal import samples 
of manufacturer Y
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3.4. Discussion 
The quality of omeprazole purchased through the internet and imported into Japan 
for personal use have mostly passed in quantity and content uniformity tests, and all the 
samples passed the dissolution test. However, many of the sites were selling omeprazole 
without prescription, though omeprazole is a prescription medicine in Japan. Some sites 
did not provide a physical address or contact number. Most importantly, one did not 
deliver the advertised product to the consumer. Illicit online shops do not necessarily 
provide detailed information about proper use of their products (Nielsen & Barratt, 2009; 
Wax, 2002). As has previously been noted, there was little response to our inquiries about 
product authenticity and legality (Khan et al., 2012, Khan et al., 2011). Thus, there is a 
clear risk to consumers who purchase products via the internet. 
Another aim of this study was to assess whether there was a quality difference 
between the same products from the same manufacturer distributed in different countries. 
Indeed, we found that the quality of the products imported personally through the internet 
in Japan was much better than that of corresponding samples previously collected in 
Cambodia and Myanmar. In particular, omeprazole samples from two manufacturers, 
collected in Cambodia and Myanmar, failed dissolution tests, whereas the corresponding 
products delivered to Japan passed. For manufacturer X, the Raman-based difference in 
correspondence between personal import omeprazole and Cambodian or Myanmar 
omeprazole was 30–40% which was further supported by the PCA analysis (Figure 3.4). 
There was also a difference in the case of manufacturer Y, though it seemed smaller from 
Raman data but the PCA analysis demonstrated a clearly distinguishable variation of the 
samples (Figure 3.5). Although small variations in purity, size, strength, and other 
parameters are permitted, a difference of nearly 40% is unlikely
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to be compatible with GMP (Good Manufacturing Practice) (FDA, 2017). It has been 
reported that some manufacturers intentionally produce substandard medicines in order 
to exploit regulatory loopholes for commercial gain (Buckley & Gostin, 2013; Caudron 
et al., 2008; Johnston & Holt, 2014). We cannot rule out the possibility that this occurred 
in the present case, although it should be borne in mind that other factors, such as 
improper storage conditions in the distribution chain, might have contributed to the 
properties of the medicines.  
A limitation of this study was the relatively small number of the samples and the 
internet sites from which samples were collected. Nevertheless, we were able to identify 
suspicious sites and suspicious samples. Another limitation was the low response rate in 
authenticity investigation, highlighting the need for better cooperation from 




Omeprazole formulations are readily available online with or without a prescription. 
The quality of omeprazole purchased via the internet and personally imported into Japan 
was mostly passed in quantity and content uniformity tests, and all the samples have 
passed in the dissolution test. Nevertheless, the same products from some of the same 
manufacturers, previously collected in surveys in Cambodia and Myanmar, had proved 
unsatisfactory, especially as regards dissolution properties. Further investigation is 
needed to establish whether some manufacturers are intentionally producing substandard 
medicines for sale in certain market segments, or whether other factors are involved.
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Public health concerns of substandard antidiabetic 
medicine: Quality estimation of pioglitazone by a 
cross-sectional survey 
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4.1. Introduction 
There is evidence that both falsified and substandard medicines are a threat to the 
public health. In addition to major economic losses, these poor quality medicines make 
the patients suffer by prolonging sickness, which may lead to death (Tabernero et al., 
2015; Khan et al., 2013). Poor quality medicines may take several forms, one of them of 
which is substandard medicines according to Newton et al (Newton et al., 2011). The 
problem of substandard medicine has been persistent over a long period of time 
(Almuzaini et al., 2013; Caudron et al., 2008; Khurelbat et al., 2014) and the issue of 
substandard medicine is being overshadowed while the drug quality monitoring 
authorities are largely focusing on drug falsification (Katsnelson, 2010; Bate et al., 2008). 
The exact figure of the substandard medicine is difficult to ascertain because of the 
insufficient methodological study and reporting systems. According to a review by 
Caudron et al. the percentage of substandard medicine in several Asian and African 
countries is 8-46% (Caudron et al., 2008). A similar study in six African countries 
revealed that 35% of their total collected samples were substandard (Bate et al., 2008). 
Moreover, with the rise of e-commerce, situation of substandard medicine is being 
aggravated by the online pharmacies. This new trading system which has now become an 
integral part of life for a variety of uses has made drug sub-standardization profitable and 
alluring to the unethical manufacturers (Mackey et al., 2016; Fittler et al., 2013). 
Nowadays it is not uncommon for patients to buy medicines online with or without 
consulting physicians. Approximately 60% of internet users in some developed countries, 
such as Japan and the USA, use the internet for their health related activities (Khan et al., 
2012). There is an increased risk that this international trade in pharmaceuticals via sales 
on the internet will facilitate the entry of these poor quality products into the legitimate 
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supply chain. Regardless of this threat, as of now there was no published data on the 
quality of pioglitazone from China or Myanmar. China and Myanmar were of special 
concern as China is the second producer, after India, of most falsified or substandard 
medicines in the global market and the recent situation of Myanmar was unknown (Pan 
et al., 2016). 
Pioglitazone, a relatively new class of oral hypoglycemic agent, is one of the widely 
used drug for the treatment of Type-2 diabetes mellitus since its approval in 1999 as an 
adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes 
mellitus (Shukla & Kalra, 2011). It is sold in the market as a single product under the 
brand name Actos or in combination with metformin (Actoplus Met, Actoplus Met XR) 
and glimepiride (Duetact) (Richter et al., 2006; FDA, 2011).  
This research study was undertaken to address the aforementioned concerns and 
provide data of good methodological quality to accurately determine the quality of 
pioglitazone in China and Myanmar along with the pioglitazone sold online for personal 
use. This information will be of value to public health officials and pharmaceutical 
practitioners to reliably determine the extent of the problem, and then can serve as a valid 
comparison for future studies to evaluate interventions to improve the drug supply quality. 
It will also help guide further research to better understand the health impact of poor 
quality medications in these countries.
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4.2.1. Study design and sample collection 
Using cross-sectional sampling, samples (N = 163) were collected from the 
following sources: (a) hospitals in Shanghai, China in 2012; (b) personal purchases of 
products via internet and imported into Japan in 2013; and (c) Mandalay, Myanmar in 
Box 4: Summary of Chapter 4 
 Research focus 
 Evaluation of the quality of pioglitazone tablets collected from Myanmar and 
China as well as from the internet sources and personally imported into Japan. 
 Key findings 
 Online sites selling pioglitazone without restriction and approval is of great 
concern. 
 Substandard pioglitazone formulations are circulating in the pharmaceutical 
market of Mandalay, Myanmar. 
 Substandard pioglitazone formulations for personal use are also available from the 
internet sources. 
 Quality of pioglitazone from Shanghai was apparently satisfactory. 
 Strengths and limitation of the study 
 Samples from Shanghai were collected from the authentic sources with 
prescription. The quality test results might vary with different sample collection 
methods and analysis methods in different pharmacopoeias, so care is needed in 
comparing these results with others. 
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2015. Samples were collected from Huangpu District and Pudong New Area of Shanghai, 
China between October and December in 2012. Personally imported samples from 
internet sources were collected during the time period of September and December in 
2013. Google Japan was used as a search engine and the search term was ‘ピオグリタ
ゾン AND 個人輸入’ for Japanese language site and ‘Pioglitazone and personal import’ 
for English language site. Samples from Myanmar were collected from Mandalay region 
during September to October 2015. 
4.2.2. Sample analysis 
Sample analysis consisted of observation test, authenticity investigation, legality 
investigation, registration and pharmacopoeial analysis. 
4.2.2.1. Observation test 
Each sample was given a distinct code after receiving the shipment. Details of the 
packaging condition and label information were noted carefully. During observation, 
focus was given to the packaging and labeling, physical appearance of the tablet, their 
size, shape, color etc. according to the WHO guideline and FIP checklist for visual 
inspection of medicine (WHO, 1999; FIP, 2012) (Appendix 2). For personal import 
samples shipping to Japan from internet pharmacy, the sites were observed if it follows 
the Pharmaceutical Affairs Law (PAL) of Japan (MHLW, 1960; MHLW, 2011; MHLW, 
2013). 
4.2.2.2. Authenticity and legitimacy investigation 
For the authenticity investigation, a detailed questionnaire of the sample was sent to 
the respective manufacturer and the manufacturing country to confirm the authenticity of 
their product and the legitimacy of the manufacturer (Appendix 3, 4, 5, & 6). Each 
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questionnaire consisted of a detailed information of the product for example- 
manufacturer name, batch number, manufacturing and expiry date, dosage and strength 
of the product as was indicated by WHO (Khan et al., 2012; WHO, 1999). Registration 
status of the all the product was evaluated by visual inspection of the packaging and then 
sending a questionnaire to importing country to confirm the registration of the product 
(Appendix 7 & 8). 
4.2.3. Quality test 
4.2.3.1. Materials 
Pioglitazone hydrochloride as the reference standard, Benzophenone as an internal 
standard, methanol, acetonitrile, ammonium acetate, potassium chloride and other 
chemicals of reagent grade were procured from the Wako Pure Chemical Industries Ltd. 
Japan. Hydrochloric acid was purchased from Nacalai Tesque Inc. and acetic acid was 
purchased from Alfa Aesar. 
4.2.3.2. HPLC analytical procedure of the samples 
Analysis of the sample was done according to the modified and validated JP 
(Japanese Pharmacopoeia) indicated protocol and performed using HPLC (High-
Performance Liquid Chromatography) (JP, 2012; JP, 2016). HPLC analysis was carried 
out at 269 wavelengths in a Prominence HPLC Shimadzu (Photo Diode Array Detector, 
SPD-20A/20AV Series) with Phenomenex Gemini NX C18 column (150 x 4.6 mm). Flow 
rate, injection volume, and detection wavelength were kept identical throughout the entire 
analysis. The dissolution test was performed with an NTR-VS 6P dissolution apparatus 
(Toyama Sangyo Co. Ltd., Osaka, Japan). Drug release studies were carried out by the 
USP Type II paddle method. The paddle was set to rotate at 50 rpm for 45 minutes and 
the temperature was maintained at 37 ±0.50 ºC. Standard solutions were prepared by 
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dissolving accurately weighed quantities of Pioglitazone Hydrochloride (reference 
standard) and Benzophenone (internal standard) in the diluent to obtain solutions with 
concentrations of 0.2 mg/mL and 0.1 mg/mL, respectively. Several dilutions were made 
to bring the final concentration of 0.025 mg/ml. The concentration of the test solution was 
kept to 0.1 mg/ml. The relationship between the peak area and concentration of each 
reference standard was linear within the range of 25–200% of the active ingredient (r2 = 
0.999–1.000), and the quality test was performed within that range. 
4.2.3.3. Acceptance criteria 
In the pharmacopoeial test, identification (BP, 2010; USP, 34; JP, 2012; JP, 2016), 
quantity, content uniformity, and dissolution acceptance criteria of the pioglitazone HCl 
tablets were as follows- 
 Identification test 
The retention time of Pioglitazone peak of the sample solution should correspond to that 
of the standard solution. 
 Assay 
Pioglitazone HCl tablets contain the equivalent of not less than 95.0% and not more than 
10.5.0% of the labeled amount of pioglitazone. 
 Content Uniformity 
In the first stage, acceptance value of 10 tablets should be equal to or less than 15. In the 
2nd stage, AV of 30 units should be ≦ 25 and no individual content is less than [1-
(0.01*L1)]M or more than [1+(0.01*L1)] M.  Calculation of acceptance value (AV); 
AV= |M-x̄ | + KS where, M: reference value; x̄: mean of individual contents; K: 
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acceptability constant, K=2.4 when the number of unit is 10, and the K=2 when the 
number of unit is 30; S: standard deviation of the sample. 
 Dissolution test 
In dissolution test, after 45 minutes in the dissolution medium in 1st stage the percent 
release of 6 individual tablet should be not less than Q+5% (Q=80%); in the 2nd stage, 
average value of 12 units should be greater than or equal to Q & no unit should be Q-15% 
(Q=80%); and in the 3rd stage, average value of 24 units should be greater than or equal 




A total of 163 samples were collected for this study. Among these, n=44 samples 
were from Shanghai, China, n=60 sample from Mandalay, Myanmar and n=59 samples 
were from internet sources and personally imported samples to Japan. The details of the 
sample location and number of samples along with their strength are outlined in Table 4.1. 
 
4.3.1. Observation of the samples and the online sites 
No unusual or suspicious information was found for any sample during visual 
inspection of the samples except for two samples from one manufacturer where two 
different batch numbered strips were found in one box. The physical appearance of the 
samples was also acceptable. However, some serious issues like selling medicines without 
prescription or delivering the different amount of ordered tablets were observed for the 
online sites during purchase of samples for personal import. Among the 32 online site 
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visited to buy 59 samples, some online sites seemed not to follow the required regulation. 
Site observation result of online pharmacies is outlined in Table 4.2. 
 
Table 4.1: Outline of the samples by sampling site, category and strength 
 
Sampling Site Year Category 
Strength 
15 mg 30 mg 45 mg Total 
Shanghai, China (Chang, 2014) 2012 
Brand 9 - - 
44 
Generic 35 - - 
Personal import samples 2013 
Brand 19 4 5 
59 
Generic 19 9 3 
Mandalay, Myanmar 2015 
Brand 1 - - 
60 
Generic 59 - - 
Total number of samples n = 163 
 
Table 4.2: Online sites observation result 
 
Category Number of sites (n=32) 
Site without any physical address 6 (18.8%) 
Site without contact number 13 (40%) 
Site without purchasing amount restriction 14 (43.8%) 
Site without prescription requirement 32 (100%) 
Site without approval of selling 45 mg Pioglitazone in Japan 4 (12.5%) 
Site delivering different amount of tablets ordered 4 (12.5%) 
 
4.3.2. Authenticity investigation 
Each manufacturer and the manufacturing country was sent request along with the 
questionnaire to verify the authenticity and legitimacy of the product and manufacturer 
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respectively. But the authenticity of the product and legitimacy of the manufacturer 
remained unclear as there was a little response from the manufacturer as well as from the 
manufacturing country. Those who replied who replied confirmed their sample to be 
genuine. In the case manufacturing country, the best response was found for the personal 
import samples where 5 out of 7 manufacturing country ensured that these manufacturers 
had the approval to manufacture pioglitazone product. Results of authenticity 
investigation is given in Table 4.3. 
 









Yes No Unknown 
China (Chang, 
2014) 
Manufacturer 1 (9) 9 (35)    
Manufacturing 
country 




Manufacturer 1 (11) 28 (59)    
Manufacturing 
country 
5 (7) 37 (59)    
Myanmar 
Manufacturer 2 (6) 9 (60)    
Manufacturing 
country 
1 (4) 1 (60)    
 
4.3.3. Quality test result 
After the final assessment, quality test results of the sample from Shanghai was found 
satisfactory where only 1 sample failed to meet the pharmacopoeial requirement. The 
average quantity of API (active pharmaceutical ingredient) in all the samples was 
98.1%±2.7 (mean±SD) of label claim and the acceptance value (AV) for uniformity of 
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content of all samples was below 15. However, in the case of samples from Myanmar and 
personal import, dissolution of the pioglitazone tablet in the dissolution medium was the 
main concern. For personal import, 38% generic samples were found to be failed among 
the 13 samples analyzed. 
 
Table 4.4: Summary of the quality test results of pioglitazone hydrochloride 
 
Sampling Site Year Test 
Test n (%) 
Brand Generic Total 








9 (100) 0 (0) 35 (100) 0 (0) 








19 (100) 0 (0) 13 (100)7 0 (0)8 








1 (100) 0 (0) 59 (98) 1 (2) 
Dissolution 1 (100) 0 (0) 51 (86) 8 (14) 
Total number of samples n = 163 
                                                     
5 Among the 31 generic samples, tests were done only for 13 samples as there was not enough tablets 
to conduct the full test. 
6 See supra note 5 
7 See supra note 5 
8 See supra note 5 
9 See supra note 5 
10 See supra note 5 
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In Myanmar 2015, among the collected 60 samples 13.3% samples were found to be 
failed. Summary of the quality test results is shown in Table 4.4 and the details of the 
quality test results of pioglitazone from Myanmar 2015 are presented in Appx 14-16. 
The average percent release of the passed samples in the dissolution medium was 
95.0±3.9 (mean±SD) and the average percent release of each failed sample is presented 
in Table 4.5. Drug release studies of the failed samples for a longer period of time 
indicated that they did not meet the threshold requirement of time to be dissolved in the 
dissolution medium and remained intact (Fig 4.1 and 4.2). Most of the tablet remained 
intact even without disintegrating in the dissolution medium (Fig 4.3 A and B). Overall, 
the quality test results of brand samples were quite satisfactory whereas generic samples 
raise a serious concern. 
Table 4.5: Average percent release of the failed samples in dissolution test (Q= 80% 
of label claim in 45 minutes) 
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Figure 4.1: Dissolution profile of standard sample and failed personal import sample 




Figure 4.2: Dissolution profile of standard sample and failed Myanmar sample for 
120 minutes (Q= 80% of label claim in 45 minutes)
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Figure 4.3: Undissolved tablet in the dissolution vessel. A) personal import sample and 




Access to good quality medicines is a key component of the quality health system. 
This study finding indicates several problems that may hinder the access of diabetic 
patients to pioglitazone of reliable quality. Although our observation of the samples did 
not lead us to any unusual finding, careful observation of the online site has revealed 
some serious issues that should no longer be ignored. According to Pharmaceutical 
Affairs Law (PAL) in Japan selling of prescription drug without prescription is strictly 
prohibited (MHLW, 1960; MHLW, 2011; MHLW, 2013), but among the 32 site visited no 
online pharmacy required prescription to sell pioglitazone. Additionally, 45 mg 
pioglitazone is not approved to be sold yet 4 pharmacies were found to be selling 45 mg 
pioglitazone. 14 pharmacies were selling without any restriction in purchasing amount. 
Surprisingly, most of the samples found to be failed in quality test were purchased from 
  
A     B 
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the site that did not reveal any physical address. In the case of Myanmar samples, all the 
samples collected for our study were of foreign origin which indicates that all of the needs 
of antidiabetic medicine is met by foreign manufacturers. This finding may indicate that 
when there are unmet needs from internal sources and a weak enforcement of regulations, 
medicines can enter the country through unauthorized channels. The authenticity of the 
product and legitimacy of the manufacturer remained unclear as there was a little response 
as observed previously (Khan et al., 2010; Khan et al., 2011). In such a case, it can be 
assumed that the manufacturer is already aware of the distribution of low-quality products 
in the pharmaceutical market. 
In our study, quality analysis of the sample from Shanghai, China was satisfactory 
where only 1 sample out of 52 sample failed to meet the pharmacopoeial requirement of 
API (active pharmaceutical ingredient). Our study suggests that quality of pioglitazone 
from Shanghai may not be that big problem as it’s claimed or it is because the samples 
from Shanghai were collected from authentic sources using prescription (Khan et al., 
2012; Delepierre et al., 2012; Kelesidis et al., 2015).  
For imported and Myanmar pioglitazone samples, dissolution was the main problem 
where the tablets failed repeatedly to disintegrate and dissolve in the medium indicating 
the solubility problem. For personally imported pioglitazone from online sites, 
substandard pioglitazone amounted up to 8.5% of total sample collected. 3 personally 
imported samples failed seriously in dissolution test, drug release amount of which was 
below 30% (Table 4.5). For that three samples, no reliable comparator was available to 
be confirmed that these samples were falsified. For Myanmar sample the failure rate was 
even higher than the personal import samples, which was 13.3%. The dissolution profile 
of these failed samples indicated that they need much longer time to dissolve 
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properly in the medium. While the sample were crushed into powder form and allowed 
in the medium, percent dissolution was higher than the tablet. 
In contempt of the apparent satisfaction about the quality of pioglitazone samples 
collected from China, substandard pioglitazone from internet and Myanmar was the key 
issue. The substandard antidiabetic medicine that would not have had any antidiabetic 
effect would have been a waste of patient’s money. The internet pharmacies those are 
selling pioglitazone online without restriction and approval is also of great concern. 
This study had limitations. Since the samples were collected by a cross-sectional 
method from a specific area, this result does not represent the actual situation of another 
region. In this study, we only focused on pioglitazone samples hence the findings cannot 
be translated for other medicines’ scenario. We could not validate the regulatory status of 
our samples due to lower response rate from manufacturer and manufacturing country. 
The failure rate of drugs might vary greatly with different sample collection methods and 
analysis methods in different pharmacopeias, so the comparison between our results and 




Even though the evidence from study findings suggests that pioglitazone samples 
collected from China were of acceptable quality, substandard medicines may continue to 
be available in internet and Myanmar. In contempt of the apparent satisfaction about the 
quality of pioglitazone samples collected from Shanghai, substandard pioglitazone from 
internet and Myanmar was the key issue. These poor quality medicines failing to dissolve 
properly after ingestion will lead to ineffective treatment because of their lacking in 
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therapeutic efficacy and may pose great health risks to patients. Additionally, internet sites 
who do not follow the regulation may accelerate the circulation of the substandard 
pioglitazone. Therefore, reinforcing and maintaining the national and international 
regulatory oversight is needed to stop spreading the poor quality medicines.
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5.1. Introduction 
Falsified medicines may lead to avoidable morbidity, mortality, drug resistance, 
early death, or treatment failure, as well as loss of faith in health systems, especially in 
low-income and middle-income countries, and therefore a reliable supply of good-quality 
medicines is essential for public health (Kelesidis & Falagas, 2015; Newton et al., 2014). 
However, it has been difficult to quantify the impact on patients’ health, because of 
fragmented and incomplete reporting of incidents and because the consequences of 
falsified medicines may range from no effect at all to enabling disease progression (Cheng, 
2009), or to lethal toxicity, as in the case of diethylene glycol-containing cough syrup 
(Rentz, 2008; Hanif et al., 1995). Also, inadequate doses of anti-infectives may lead to 
drug resistance (Alfadl et al., 2008; Mackey & Liang, 2011). 
With the exponential increase in internet connectivity, those engaged in distribution 
of falsified medical products have gained access to a global market place (Venhuis et al., 
2014), and no country remains untouched by this issue. The growth of a culture of self-
diagnosis and self-prescribing has led to the emergence of thousands of unregulated 
websites providing unsupervised access to medical products with no guarantee of 
authenticity (Cicero et al., 2012). Thus, what was once considered a problem suffered by 
developing and low-income countries has now become an issue for all, although low- and 
middle-income countries and areas of conflict or unrest are still most vulnerable to 
falsified medical products owing to inadequate health-related regulatory systems. 
Falsified medical products are generally difficult to detect, as they are usually 
designed to appear identical to the genuine product and may not cause an obvious adverse 
reaction, although they may be ineffective. Falsification can be intentional, accidental, or 
due to negligence, and may involve medicines with no API (active pharmaceutical 
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ingredient), the wrong API, an inappropriate amount of API, potentially resulting in zero 
efficacy, some efficacy, or toxicity (WHO, 2010). It may involve diverted, re-labeled, re-
packaged, or mixed products (WHO, 2017a). There is currently no universally agreed 
definition of what used to be widely known as ‘counterfeit medicines’ (WHO, 2017b). 
According to Newton et al., the term should be used to describe products that are 
deliberately and fraudulently mislabeled with respect to identity and/or source, including 
products with correct or incorrect ingredients, without active ingredients, with insufficient 
active ingredient, or with fake packaging (Newton et al., 2010). The US FDA (United 
States Food and Drug Administration) definition includes products that may be 
contaminated or contain the wrong or no active ingredient, or the right active ingredient 
but at the wrong dose (US-FDA, 2017). The EU (European Union) includes products that 
might contain ingredients, including active ingredients, of poor quality or at the wrong 
dose, but pass themselves off as real, authorized medicines. The term "falsified" refers to 
all forms of falsification, while the term "counterfeit" specifically refers to an 
infringement of intellectual property rights. Falsifications are becoming more 
sophisticated (EU, 2017), and falsified medicines can be found in illegal street markets 
or obtained via unregulated websites, and have been detected even in pharmacies, clinics 
and hospitals (Buckley & Gostin, 2013). 
The purpose of this research is to study the literature describing the health 
consequences of falsified medicines, focusing on mortality and morbidity, as well as the 
scale of the issue, the geographic extent, the medicines affected, and the harm caused at 
both the individual and population levels. We do not attempt to present an exhaustive 
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analysis of every health consequence of substandard or falsified drugs, but aim to give an 





This study of the literature is based on searches performed in PubMed. Four authors 
(MSR, NT, JE, OM) independently performed the literature search, selection of relevant 
articles, and data extraction. 
5.2.1. Stage 1 
Initially, articles were hand-searched in PubMed using different combinations of key 
words to identify relevant articles, aiming to optimize keyword selection. The key words 
were “(counterfeit OR fake) AND (medicine OR drug) AND (problem OR safety OR 
threat OR victim OR hazard OR harm OR injury OR impact OR damage)”. In addition, 
MeSH search was conducted using the keyword ‘counterfeit’ or ‘fake’. We then examined 
Box 5: Key points of Chapter 5 
 PubMed was searched to identify reports about the effects of falsified 
medicines. 
 A total of 82 English-language articles were identified, categorized, and 
tabulated the data. 
 All types of medications have been falsified, affecting both children and 
adults. 
 Numbers of incidents were similar in developing and developed countries. 
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the search results for articles written in English that described the health impact and 
causes of falsified medicines. 
5.2.2. Stage 2 
Based on the results of Stage 1, we focused on the search words ‘‘(counterfeit OR 
fake OR bogus OR falsified OR spurious) AND (medicine OR drug)’’, because the terms 
‘counterfeit’, ‘spurious’ and ‘falsified’ have been defined by WHO (WHO, 2017b), and 
the terms ‘bogus’ and fake’ were frequently found in connection with falsified medicine 
in the articles identified in Stage 1 (Lancet, 1924; Dondorp et al., 2004). Selection criteria 
for articles were the same as in Stage 1. 
5.2.3. Stage 3 
After consideration of the results from Stage 2, we next conducted a search of 
PubMed for the year 2010 using the various combination of keywords ‘‘(counterfeit OR 
fake OR bogus OR falsified OR spurious) AND (medicine OR drug)’’. This search hit 
1700 articles in total, and a review of these articles yielded 11 describing health damage 
due to falsified medicine, 7 describing health damage not due to falsified medicine, and 
18 not reporting health damage. 
Keywords were extracted from the abstract of each of these articles using the IBM 
SPSS Text Analytics. Then, using the same keywords, the PubMed search result was 
compared with the results from other databases (Google Scholar, Scopus, Web of Science). 
For the same keywords, most of the relevant articles were picked up in the PubMed 
database, whereas more were missed in the other databases. Therefore, PubMed was 
selected the preferred database for the present purpose.
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5.2.4. Data extraction criteria of the selected articles 
Based on the above findings, a comprehensive search of PubMed was conducted on 
February 2013. Three additional searches were conducted between March 2013 and 
February 2017. The search term was ‘‘(counterfeit OR fake OR bogus OR falsified OR 
spurious) AND (medicine OR drug)’’. From the hits, we selected English language 
articles describing damage to patients’ health due to falsified medicines. When possible, 
primary sources (reporting the outbreak or case studies) have been cited; data from 
publications were included and tabulated if they provided examples of serious health 
hazards, adverse reactions, injury, or deaths. There were some articles among the searched 
articles in which the terms false, deliberate contamination or adulteration were used to 
describe apparently falsified drugs. Incidents described in these articles were judged as 
falsified medicine incidents and data from these articles were included. 
5.2.5. Statistical analysis 
Results are summarized as descriptive statistics and expressed as number and 
percent. Graphs were prepared using Microsoft Excel 2010. IBM SPSS Text Analytics 
2013 version was used for the keyword selection. 
 
 
5.3. Results and discussion 
Among the 1,608 articles hit in the final search using the selected key words, English 
language articles with a full text amounted to 1477. The additional searches between 
February 2013 and February 2017 yielded 398 articles, of which 314 articles were full-
text English language articles. These articles reported a total of 49 incidents related to 
falsified drugs (Table 5.1) describing 7200 causalities among which 3604 people died 
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(death rate 50.1%). In table 1, two cases were not included although there have been 
several reports (Cheng, 2209; Cockburn et al., 2005; Deisingh, 2005; Newton et al., 2006; 
Ziance, 2008; Wertheimer et al., 2003) that in 2001 alone, a total of 192,000 people died 
due to fake medicines in China, as first reported by a government-owned newspaper, 
Shenzhen Evening News (Fackler, 2002). Regarding this specific case, one of the Chinese 
official confirmed that the incidence of 192,000 peoples’ death was mistakenly translated 
by a journalist where the reason was mentioned as due to falsified medicines. The second 
case was also in China where, diethylene glycol contamination of paracetamol syrup 
killed 192,000 people in 2002 (Jackson et al., 2010). However, no details were reported 
on specific drugs or therapeutic categories of drugs involved, although it is possible that 
second case refers to the same incident, as the reported number of people affected was 
the same. Some cases were regarded as duplicates, because health damage, occurrence 
year, country, drugs and cause were the same. 
5.3.1. Geographical distribution of incidents 
Among the total reported incidents involving health damage due to falsified 
medicines (n=49), 27 (55.1%) occurred in developing countries. The other 22 (44.9%) 
incidents have occurred in developed countries (World Bank, 2017). The distribution of 
these incidents among regions is shown in Fig 5.1. The 2006 estimate of falsified 
medicines by WHO indicated that the prevalence of falsified medicines ranged from less 
than 1% in developed countries to over 10% developing countries (WHO, 2006). But, it 
is noteworthy that our results show that the difference between developing and developed 
countries is quite small in terms of the number of incidents where falsified 
pharmaceuticals actually impacted on human health. 
 
Chapter 5- Results & Discussion 
Evaluating the quality of lifetime medicines- results from Asia and the health consequences of 




Figure 5.1: Prevalence of the health damage incidents by region. (Others= Australia, 
unknown) 
 
What was once regarded a problem mostly affecting developing and low-income 
countries now seems a serious issue for all (WHO, 2017). Surprisingly, the USA alone 
accounted for 25% of the total incidents reported. Since 2001, at least 10 drug falsification 
incidents affecting patients were reported, although the US-FDA suggests that drug 
counterfeiting occurs less frequently in the U.S. than in other countries due to their strict 
regulatory framework (US-FDA, 2017). This strict framework may mean that incidents 
are reported in the US that would have been overlooked or not reported in other countries 
with less well developed heath systems.  
Incidents were also reported in other developed countries: Australia, Canada, 
Singapore, UK, Japan, Russia, and Norway. Among developing countries, Nigeria was 
the victim of repeated incidents of harm caused by falsified drugs, with the latest (falsified 
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Among other developing countries, 2500 people died in Niger after receiving fake 
meningitis vaccine. Another report mentioned the death of 700,000 people due to fake 
anti-malarial and tuberculosis drugs, but gave no details as to the country involved, or the 
year (Table 5.1, case 48). There were also several cases for which enough details were 
not found to categorize it specifically as in case 42 of Table 5.1, where the sequence of 
supply chain was not clear to confirm if it was a medication error or the IV fluid was 
deliberately mislabeled. In a usual condition, simulated IV fluid for educational purpose 
is not entitled to be used for regular patients. 
 
Table 5.1: Summary of incidents of falsified medicines causing health damage, 
including deaths or adverse reactions. In some cases, different numbers of injuries in 
the same incident were given in different articles. In cases where multiple articles give 
the same number, that number is shown; otherwise the maximum reported number of 





Country Health Impact Cause Reference(s) 
01 1969 South Africa 7 children died 
Diethylene glycol poisoning from sedative 
mixtures 
Bonati, 2009; Alkahtani et 
al., 2010; Bowie, 1972 
02 1982 USA 7 people died Cyanide-laced paracetamol Cockburn et al., 2005 
03 1986 India 14 patients died 
Receiving doses of impure glycerin 
contaminated with diethylene glycol 
Pandya, 1988; Gautam et 
al., 2009 
04 1988 Nigeria 
A 21-year-old woman 
died 
Hyperglycemia due to fake insulin Cheng, 2009 
05 1989 Haiti 89 people died 
Paracetamol cough syrup prepared with 
diethylene glycol 
Cohen et al., 2007 
06 1990 Nigeria 109 children died 
Acute renal failure from diethylene glycol 
contaminated syrup/elixir 
Alfadl et al., 2013; Bonati, 
2009; Alkahtani et al., 
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2010, Cockburn et al., 
2005; Gautam et al., 2009; 
ten Ham, 1992; 
Okuonghae et al., 1992; 
Alubo, 1994; Stearn, 2004; 
Deisingh, 2005; Garuba et 
al., 2009; Hellstrom, 2011; 
Oshikoya & Senbanjo, 
2010; Hall et al., 2006;  
Newton et al., 2006a; 
Reidenberg & Conner,  
2001; Roger & Boateng, 
2007 
07 1990 Bangladesh 
236 patient died 
including 51 children 
Paracetamol syrup tainted with diethylene 
glycol 
Hanif et al., 1995; Bonati, 
2009; Alkahtani et al., 
2010; Cockburn et al., 
2005; Gautam et al., 2009; 
Hall et al., 2006;  Newton 
et al., 2006a; Reidenberg & 
Conner,  2001; Roger & 
Boateng, 2007;  
Manchester, 2005 
08 1992 Argentina 26 people died 
Consumption of a propolis syrup with 
high level of diethylene glycol 
O'Brien et al., 1998; 
Alkahtani et al., 2010; 
Cockburn et al., 2005; 
Gautam et al., 2009; 
Newton et al., 2006a; 
Reidenberg & Conner,  
2001; Roger & Boateng, 
2007 
09 1995 Haiti 85 children died 
Ingestion of paracetamol 
syrup adulterated with diethylene glycol 
Alfadl et al., 2013; O'Brien 
et al., 1998; Bonati, 2009; 
Alkahtani et al., 2010; 
Cockburn et al., 2005; 
Stearn, 2004; Deisingh, 
2005; Hall et al., 2006;  
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Newton et al., 2006a; 
Reidenberg & Conner,  
2001; Roger & Boateng, 
2007; CDC, 1996; Junod, 
2000; Rassool, 2004; 
Wertheimer & Santella, 
2005; Burki, 2010; Ziance, 
2008; Wertheimer, 2003; 
Baratta et al., 2012; ten 
Ham, 2003 
10 1995 Niger 2500 people died Counterfeit meningitis vaccine 
Alfadl et al., 2013; Stearn, 
2004; Rassool, 2004; 
Wertheimer & Santella, 
2005; Burki, 2010; Ziance, 
2008; Baratta et al., 2012; 
Mukhopadhyay, 2007; 
Nsimba, 2008; Wertheimer 
& Norris, 2009; Reynolds 
& McKee, 2010 
11 1998 Brazil 
200 unwanted 
pregnancies 
Dummy contraceptive pill 
Stearn, 2004; Deisingh, 
2005; Reidenberg & 
Conner, 2001; Wertheimer 
& Santella, 2005; Ziance, 
2008; Wertheimer et al., 
2003; Csillag, 1998 
12 1998 India 
36 children suffered acute 
renal failure, 33 of them 
died 
Cough expectorant contaminated with 
diethylene glycol 
Bonati, 2009; Alkahtani, et 
al., 2010; Cockburn et al., 
2005; Gautam et al., 2009; 
Deisingh, 2005; Hellstrom, 
2011; Hall et al., 2006; 
Newton et al., 2006a; 
Reidenberg & Conner, 
2001; Roger & Boateng, 
2007; Rassool, 2004; 
Mukhopadhyay, 2007; 
Kumar, 2001; Singh et al., 
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1998; Hari et al., 2006 
13 1998 Brazil Several people died Dummy anticancer drug 
Reidenberg & Conner, 
2001; Csillag, 1998 
14 1998 Russia 
1000 patients were 
hospitalized 
Counterfeit insulin Ziance, 2008 
15 1999 Cambodia 30 people died 
Counterfeit artesunate prepared with 
suphadoxine-pyrimethamine 
Roger & Boateng, 2007; 
Rassool, 2004; 
Mukhopadhyay, 2007 
16 1999 USA 
17 deaths and 254 with 
adverse effects 
Counterfeit gentamicin Moken, 2003 
17 2001 USA 
Several patients suffered 
tissue swelling or skin 
rashes in seven states 
Injection of fake growth hormone Editorial, 2001 
18 2002 USA 
A 16-year-old boy 
suffered painful spasms 
Injection of diverted drug containing very 
low amount of epogen 
Dooley et al., 2010 
19 2002 USA A cancer patient died Counterfeit Procrit Lawler, 2009 
20 2004 Nigeria 
3 hospitals reported cases 
of adverse reaction 
Infusion contaminated with 
microorganism 
Garuba et al., 2009 
21 2004 Canada 4 people died 
Heart attacks and strokes after taking 
Norvasc copycats made from pressed talc 
Teichman, 2007 
22 2004 Argentina 
2 woman died and one 
gave premature birth to 
26 week premature baby 
Counterfeit iron injection for anemia Stoneman et al., 2011 
23 2005 USA 5 men died 
Ingestion of misbranded 
dextromethorphan 
Ziance, 2008 
24 2005 USA 
Respiratory paralysis of 
several people 
Fake version of Botox Liang, 2006 
25 2005 Myanmar 
A 23-year-old man died 
from cerebral malaria 
Artesunate tablet containing paracetamol 
as a main ingredient 
Newton et al., 2006b; 
Atemnkeng et al., 2007 
26 2006 Canada 4 people died 
Unauthorized substitution of counterfeit 
viagra containing talcum powder 
Cheng &, Shaughnessy, 
2008 
27 2006 Panama 
200 people died 
including more than 100 
children 
Paracetamol cough syrup contaminated 
with diethylene glycol 
Rentz et al., 2006; Alfadl et 
al., 2013; Reynolds & 
McKee, 2010; Seiter, 2009; 
Marini et al., 2010 
28 2007 Canada A 58-year-old woman Counterfeit zolpidem and acetaminophen Teichman, 2007; Cheng &, 
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died Shaughnessy, 2008; 
Jackson et al., 2012 
29 2007 Hong Kong 
10 non-diabetic patients 
were hospitalized due to 
hypoglycemia including 
1 death and another taken 
to ICU 
Herbal drug for erectile dysfunction; 
(yellow capsules labeled as 假偉哥 and 
red/pink capsules named as “Nangen” ) 
containing glibenclamide 
Kao et al., 2009 
30 2008 China 12 patients died 
Armillarisin manufactured with 
diethylene glycol as a solvent 
Alkahtani et al., 2010; Lin 
et al., 2008 
31 2008 USA 
785 adverse reaction 
reports including 81 
deaths 
Counterfeit heparin contaminated with 
oversulfated chondroitin sulphate 
Alfadl et al., 2013; 
Editorial, 2008; Lewis, 
2009; Labadie, 2012 
32 2008 Singapore 
150 patients were 
hospitalized, 7 remained 
comatose and 4 
subsequently died. 
counterfeit Cialis (tadalafil), three herbal 
preparations and sildenafil 
Hellstrom, 2011; Kao et 
al., 2009; Sugita & 
Miyakawa, 2010; WHO, 
2010; Liang & Mackey, 
2012 
33 2008 Norway 
44 people were suffering 
from poisoning 
Fake flunitrazepam tablets containing 
scopolamine 
Vallersnes et al., 2009 
34 2008 Nigeria 118 children died 
Paracetamol teething mixture containing 
diethylene glycol 
Bonati, 2009; Alkahtani et 
al., 2010; Oshikoya & 
Senbanjo, 2010; Reynolds 
& McKee, 2010; Seiter, 
2009 
35 2009 China 2 people died 
Counterfeit glibenclamide 6 times more 
potent than normal 
Cheng, 2009; Lewis, 2009; 
Holzgrabe & Malet-
Martino, 2011 
36 2010 Australia 
A 54-year-old man s 
suffered severe 
hypoglycemia 
Ingestion of counterfeit Cialis Chaubey et al., 2010 
37 2010 China 
81 patients were 









74 patients had 
recurrence or increased 
frequency of seizures, 2 
Falsified phenobarbital Otte et al., 2015 
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subsequently died 
39 2014 Unknown 
A 65-year-old male 
suffered hepatotoxicity 
Chinese herbal medicine containing 
sildenafil 
Nissan et al., 2016 
40 2014 Nigeria 
105 patients had 
increased frequency of 
seizures 
Falsified phenobarbital Otte et al., 2015 
41 2014 Congo 
930 people suffered 
dystonic reactions, 11 
among them died 
Falsified diazepam containing haloperidol Peyraud et al., 2017 
42 2014 USA 
40 patients suffered 
adverse events including 
one death. 
Non-sterile simulated IV fluids containing 
large amounts of endotoxin and 
significant bacterial contamination 
Torrie et al., 2016 
43 2015 USA 
8 people suffered adverse 
effects 
Ingestion of counterfeit alprazolam tablets 
found to contain fentanyl and, in some 
cases, etizolam 
Arens et al., 2016 
44 2015 India 
15 patients suffered 
intraocular inflammation 
Injections of counterfeit bevacizumab Stewart et al., 2016 
45 2016 USA 
7 people suffered adverse 
effects 
Norco (acetaminophen and hydrocodone), 
containing fentanyl and promethazine. 
Vo et al., 2016 
46 Unknown UK 
Acute lead intoxication in 
one man 
Falsified ayurvedic drug for erectile 
dysfunction (Kamagra) 
Barber & Jacyna, 2011 
47 Unknown USA 
A child complained of 
burning sensation after 
injection with human 
growth hormone 
Human growth hormone containing 
inexpensive insulin 
Vastag, 2003 
48 Unknown Unknown 700,000 deaths Counterfeit malaria and tuberculosis drug 
Alfadl et al., 2013; Mackey 
& Liang, 2011 
49 Unknown Japan 
A 39-year-old man was 
suffering from 
hypoglycemia 
Sexual enhancement medication 
containing extremely large amount of 
glibenclamide and a small amount of 
sildenafil 
Kuramoto et al., 2015 
 
5.3.2. Therapeutic category 
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Among the categories of falsified drugs that caused health damage, sedatives, 
hypnotics, narcotics and, drugs for sexual dysfunction were the most common in both 
developing countries and developed countries. On the other hand, patients from 
developing or underdeveloped countries were mainly affected by falsified antipyretics, 
analgesics, and antitussives, such as paracetamol elixir, cough syrup, or teething mixture 
containing diethylene glycol (Alkahtani et al., 2010; Lin et al., 2008). Unfortunately, 
reports of very large numbers of deaths (Table 5.1, case 49) gave very few details, and 
could not be verified. Overall, the number of incidents by drug therapeutic category is 




Figure 5.2: Number of incidents by drug therapeutic category. (Others=Anticancer, 
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5.3.3. Annual trends in number of incidents and number of persons affected by 
falsified medicines 
According to the PSI, the global incidence of drug counterfeiting has increased by 
51% between 2011 and 2015, with 2015 seeing the highest level of counterfeiting to date, 
a 38% increase compared with 2014. The Institute documented 3,002 incidents of 
pharmaceutical crime during 2015 alone (PSI, 2017). Regarding health damage from 
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Figure 5.3: Yearly cases of health damage caused by falsified medicine (n=41). A total 
of 8 cases were not included to the chart as there was no clear indication of occurrence 
year (n=3), location (n=2), number of injuries (n=4), or medicine involved (n=2) 
On the other hand, Fig 5.4 shows the numbers of persons affected during various 
time periods. No clear trends can be seen in either the number of incidents (Figure 3) or 
the numbers of people affected (Figure 4), although it is important to note that these 
figures exclude cases where insufficient information was available in published reports 
(see figure legends for details). 
 
 
Figure 5.4: Number of health damage incidents of falsified medicine by Year (n=46). 
3 cases were not included as there was no mentioning of occurrence year. 
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The identified incidents involved many kinds of falsified drug products. Some did not 
contain any active ingredient (meningitis vaccine containing no active ingredient or just 
salt water), or included the active ingredient in harmful amounts (traditional anti-diabetic 
medicine containing six times the normal dose of glibenclamide). Others involved a 
completely different active ingredient or incorrect formulation, or contained unacceptably 
high levels of impurities (cyanide-laced paracetamol or zolpidem and acetaminophen 
laced with metal). 
Looking at the health damage caused by falsified drugs at Table 5.1, the most common 
category (10 cases) covered antipyretic, analgesics, (acetaminophen, paracetamol) 
antitussive medication (cough syrup, paracetamol, dextromethorphan), and in 8 of them, 
diethylene glycol was present as a contaminant (either deliberate or accidental) in the 
drug. Mass poisoning incidents with diethylene glycol have occurred in a number of 
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Figure 5.5: Characteristics of falsified drugs causing health damage (n=49) 
 
Medicines containing an incorrect amount of API or a totally different kind of API 
appeared in at least 12 cases. Another common finding was endotoxin and microbial 
contamination of ophthalmic products or infusions. Fig 5.5 summarizes the types of 
falsified medicines associated with health damage in the incidents listed in Table 5.1. 
 
 
5.3.5. Prospects for the fight against drug falsification 
A better understanding of falsified drug-related injuries and diseases, together with 
knowledge of the main targets of falsification are needed to develop better prevention 
strategies. To address this issue, better collaboration among concerned communities, 
including government organizations, health workers, industry and civil society, will be 
Box 6: Potential consequences of drug falsification  
 Falsified medications are associated with both direct and indirect risks to health.  
 Direct risks include unknown pharmaceutically active ingredient(s) and/or 
impurities that may lead to serious adverse effects, dosage variability or 
mislabeling potentially leading to overdose, and incorrect product descriptions 
creating a risk for drug-drug interactions.  
 Indirect risks include lack of appropriate information, lack of advice and/or 
management of healthcare concerns; difficulty of managing adverse effects caused 
by an unknown product; and unnecessary dosing changes or unwarranted dismissal 
of genuine therapies because of perceived lack of effect caused by variable potency 
of falsified products. 
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essential. Especially, communication between the healthcare professional and patients 
needs to be improved to inform and educate patients about the risks of falsified drugs. 
Public awareness concerning the potential problems of internet pharmacies and other 
online purchasing sites also needs to be raised. Management systems for the supply chain 
should be improved and the secondary drug market should be better regulated. Finally, 
post-marketing surveillance and pharmacovigilance should be strengthened to ensure 
drug safety and patient safety. 
 
5.3.6. Limitations of the study 
This study has several limitations. Firstly, it covers only English language articles in 
the PubMed database. Also, in some of the reported cases, there was no information about 
specific drug involvement, exact number of patients harmed, year of occurrence or the 
location of the incident. In particular, several incidents that were claimed to involve 
hundreds of thousands of people were very poorly described. It should also be borne in 
mind that the results might be biased by differences in the effectiveness of reporting 
systems among countries; for example, less serious incidents in under-developed 
countries might not have been reported. In addition, different reports sometimes gave 
conflicting information about the same incident. Thus, we cannot estimate the true extent 
of the problem. Nevertheless, we believe this study of reported drug falsification incidents 
involving health damage will be useful to illustrate the nature and scale of the problem, 
and to provide a basis for further surveys in the future.
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5.4. Conclusion 
It is clear from the results of this study that falsified medicines impact both directly 
and indirectly on global public health. A wide range of medicines has been falsified in a 
variety of ways, and our findings may be helpful to identify particular causes for concern, 
such as deliberate or accidental contamination with ethylene glycol. Recognition of the 
problem, coordination of responses, and active engagement of key stakeholders will be 
essential in combating transnational pharmaceutical crime, and reducing the human cost 
of falsified medicines.
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Chapter 6 
General conclusion and future directions 
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6.1. Conclusion 
This research addresses several key issues that may influence future trends in the 
prevalence of substandard pharmaceuticals in South Asian countries. In today’s context 
of globalization of pharmaceutical production and distribution, the findings of this study 
highlight the urgency of implementing continuous and ongoing monitoring of the quality 
of drugs as a basis for designing and implementing appropriate countermeasure to prevent 
the manufacture and distribution of both substandard and falsified medicines in this 
region. The inadequacy of the current regulatory requirements and systems in resource-
poor settings provides unscrupulous manufacturers with the opportunity to sell poor 
quality medicines with little risk of being sanctioned. This situation is exacerbated by the 
current high demand for lifestyle medicines, favoring the interests of manufactures with 
poor technical capacity or with poor ethics, but certainly not serving the interests of the 
importing countries or the patients (Ravinetto et al., 2012). 
Regarding the authenticity of the medicines and the legitimacy of the manufacturer 
and distributors, we could not clearly establish the facts, because we received little 
response to our enquiries from either side, as has been the case in previous studies. 
Nevertheless, the production of substandard medicines appears to be a vast and 
underreported problem, which particularly affects poorer countries. Often, investigators 
have found that pharmaceutical companies and governments are reluctant to respond to 
requests to confirm the authenticity of the product or the legitimacy of the manufacturers 
and distributors (Khan et al., 2009; Khan et al., 2010; Khan et al., 2012; Yoshida et al., 
2014; Rahman et al., 2017). In the case of manufacturers, one of the reason may be that 
publicity would harm the sales of brand name products in a fiercely competitive business. 
We suggest that this situation is not in the long-term interests of the legitimate 
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pharmaceutical industry. We urge a change to mandatory reporting to governmental 
authorities, which should also have a legal duty to investigate, provide appropriate 
information, and share information across borders. This is not a role for the 
pharmaceutical industry, which appears to have a serious conflict of interest. 
 
 
Moreover, the internet, has now become the source of health-related information for 
millions of people (FDA, 2017; Fernandez et al., 2008). Many online sites are selling 
medicines for personal use, particularly omeprazole and pioglitazone, without restriction 
or approval. It is clear that the internet is having a great impact (Orizio et al., 2009; Siva, 
2009).  More than half of the sites that we found did not declare their physical location, 
and a majority of sites did not ask for a medical prescription in order to purchase drugs. 
Avoidance of prescription boundaries can be a potential disruptor at multiple levels, both 
at the individual level, between doctor and patient, where it represents an easy way to 
overcome the health professional filter in order to access drugs, and at a public health 
Box 7: Significance of the study 
This work is the only recent survey of the quality of delayed-release omeprazole 
capsules and pioglitazone tablets collected in Cambodia, Myanmar, and China, or 
purchased via the internet for personal use. Significant proportions of these medicines 
were substandard, especially in the cases of samples from Myanmar and internet 
sources. Nevertheless, comparison of these findings with earlier surveys (Khan et al., 
2012; Yoshida et al., 2014) indicates that the situation in these countries has improved 
in the last few years. Our findings provide a basis for recommendations and regulatory 
actions to further improve the situation in those countries. 
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level, where national health services can be affected by patients bypassing regulated 
systems. Indeed, there have been reports of concern regarding drugs storage, shipping 
conditions, and fraudulent and dangerous practices associated with online purchase of 
medicines (Weiss, 2006). 
It should be noted that this thesis has focused on the situation of only two drugs, 
omeprazole and pioglitazone, in several Southeast Asian countries, due to limitations of 
time and resources. Our work does not imply that the issue of substandard medicines and 
variability in drug quality is of equal importance in all countries. Indeed, the problem may 
be more profound in low and middle income countries, for example, Cambodia and 
Myanmar, due to limited regulatory capacity and the high proportion of imported 
medicines. Nevertheless, despite limited resources, it will be very important for these 
countries to develop strategies for improving procurement of medicines, as well as 
involving stakeholders in evaluating the quality of medicines and making patients more 
aware of the possible consequences of taking poor quality medicines. 
 
6.2. Policy implications and future directions 
A number of important ideas and potential policy implications can be extracted from 
this report. Rather than picking a single framework, we consider that three broad policy 
goals need to be addressed – (1) increasing the national and international emphasis on 
substandard medicines, in addition to falsified medicines; (2) improving collaboration 
between medicinal regulatory authorities and manufacturers to undertake comprehensive, 
independent market surveillance in order to establish scale and scope of the problem, and 
(3) strengthening systems across the medical supply chain to improve overall supply 
chain management. There is also a need to undertake further research into the role of 
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information asymmetries in pharmaceutical supply chains, and its effect on the 
perceptions and actions of health professionals, consumers and patients. These studies 
should be performed in a manner that supports accurate cross-comparisons, and the 
results should be made available to the public. Pharmaceutical companies can also assist 
by becoming more transparent with their data on this public health challenge, as well as 
alerting the public promptly to potential cases of poor quality medicines. As more and 
more middle-income countries are emerging as important sources of pharmaceutical 
ingredients and finished medicinal products, there is an increasing need for 
comprehensive and harmonized strategies to address variability in drug quality.
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LIST OF APPENDICES 
 
Appendix 1: Sampling form 
 
PRODUCT INFORMATION
Trade name of the product 
Name of active ingredients
Are there any loose medicines?
□the original one supplied during the
procurement
□changed later on in the drug store
For Loose medicine, the container is
 □Unknown
 Information Source
 □Label   □Verbal
□ Yes                □ No
No. of other staff
Label
Salt form   
The product is
            
□　Domestically produced     □　Imported
Verba l
Unk nown
In forma t i on  Sour ce
Contents
Dose form of products □Tablets    □Capsules □Ampules    □Others :____________________
Answer
Strength per unit dose    g   /  mg   as
/ 9or10/2014
Combating Counterfeit Medicine in Myanmar: 2014 Code :           /MM14/
Sampling Form
Ser ial  No . ―





□ ①   1st (A) 　〈selected companies〉
□ ②   1st (B)   〈Loose sample〉
□ ③   random sampling
Batch/Lot number
Manufactury date      DD _________________ / MM  ________________  / YY ________________
Expiry date      DD _________________ / MM  ________________  / YY ________________
Package insert   □ Yes ⇒□Burmese □English   □French   □Others:               □ No
Registration number    □ Yes ⇒  _________________________________ 　□ No
Price per Unit
No. of Pharmacist
No. of Pharmacy Assistant
OUTLET INFORMATION
Contents Answer
Outlet address Any comments ?  (e.g. Is the medicine kept in a refrigerator ?) Signature
Name of the outlet
How many units of this medicine does the outlet sell ?                               ________________ units per  ____________________      .
(e.g. month, year)   
□ Yes                □ No
Category of the outlet
□ Hospital Pharmacy                   □Community Pharmacy
□ Wholesaler                      □Others                                 .
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Appendix 2: FIP checklist for the observation of samples 
 






1. PACKAGING       
1.1 Container and Closure       
Does the container and closure 
protect the 
product from the outside environment; 
e.g. 
is the container properly sealed? 
      
Do they assure that the product will 
meet 
the proper specifications throughout its 
shelf life? 
      
Are the container and the closure 
appropriate for the product inside? 
      
Is the container safely sealed?       
1.2 Label       
If there is a carton protecting the 
container, 
does the label on the carton match the 
label on the container? 
      
Is all information on the label 
legible and  
indelble? 
      
1.2.1 The trade (brand) name       
Is the trade name spelled correctly?       
Is the medicinal product (trade 
name) registered 
in the country by the Drug Regulatory 
Authority) ? 
Is the product legally sold in the 
coutry? 
      
Does the symbol ® follow the trade 
name? 
      
For blister or foil strip packed 
products, is the  
trade name indelibly impressed or 
imprinted onto 
the strip? 
      
1.2.2 The Active ingredient name 
(scientific name/generic name) 
      
Is the active ingredient name spelt 
correctly? 
      
Do the trade name and the active 
ingredient  
names correspond to the registered 
product? 
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1.2.3 The manufacturer's name 
and logo 
      
Are the manufacturer's name and 
logo legible and 
correct? 
      
Does the logo or hologram (if 
applicable) look  
authentic? 
      
Does the logo or hologram (if 
applicable) change colour when viewed 
from different angles? 
      
1.2.4 The manufacturer's full 
address 
      
Is the manufacturer's full address 
legible and 
correct? 
      
Has this company or its agent 
registered the  
product in the country? 
      
1.2.5 The medicine strength 
(mg/unit) 
      
Is the strength - the amount of 
active ingredient 
per unit - clearly stated on the label? 
      
For blister or foil strip packed 
products, is the 
medicine strength indelibly impressed 
or imprinted 
onto the strip? 
      
1.2.6 The dosage form (e.g., 
tablet/capsule) 
      
Is the dosage form clearly indicated 
on the 
container label? 
      
Does the dosage form stated on the 
label match 
the actual dosage form of the 
medication? 
      
Is the indicated madicine under this 
dosage form 
registered and authorised for sale in the 
country? 
      
1.2.7 The number of units per 
container 
      
Does the number of dosage units 
listed on the  
label match the number of dosage units 
stated  
on the container? 
      
1.2.8 Dosage statement (if 
appropriate) 
      
Is the dosage clearly indicated on 
the label? 
      
Is the dosage stated on the label 
appropriate for 
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the madicine in this form and strength? 
Is the product registered and 
authorised for sale 
in the country with this dosage? 
      
1.2.9 The batch (or lot) number       
Does the numbering system on the 
package 
correspond to that of the producting 
company? 
      
For blister or foil strip packed 
medicines, is the  
batch number indelibly impressed or 
imprinted onto 
the strip? 
      
1.2.10 The date of manufacture 
and the expiry date 
      
Are the manufacture and expiry 
dates clearly  
indicated on the label? 
      
For blister or foil strip packed 
products, is the  
expiry date indelibly impressed or 
imprinted onto 
the strip? 
      
1.2.11 Storage information       
Are the storage conditions indicated 
on the label? 
      
Has the product been properly 
stored? 
      
1.3 Leaflet or package insert       
Is the package insert printed on the 
same 
coloured or same quality paper as the 
original (If  
available to compare) or does it look 
familiar? 
      
Is the ink on the package insert or 
packaging 
smudge-proof? 
      
Does the informationb on the 
package insert  
match the information on the product 
container? 




      
2.1 Uniformity of Shape       
Are the tablets/capsules uniform in 
shape? 
      
2.2 Uniformity of Size       
Are the tablets/capsules uniform in 
size? 
      
2.3 Uniformity of Colour       
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Are the tablets/capsules uniform in 
colour? 
      
2.4 Uniformity of Texture       
Do the tablats have a uniform 
coating? 
      
Is the base of the tablets fully 
covered? 
      
Are the tablets unifomly polished, 
free of powder, 
and non-sticking? 
      
2.5 Markings (scoring, letters, 
etc) 
      
Are markings uniform and 
identical? 
      
Does the logo (if present) match 
that of the 
manufacturing company? 
      
2.6 Breaks, Cracks and Splits       
Are the tablets/capsules free of 
breaks, cracks, 
splits or pinholes? 
      
2.7 Embedded surface spots or 
contamination 
      
Are the tablets/capsules free of 
embedded  
surface spots and foreign particle 
contamination? 
      
2.8 Presence of empty capsules in 
the case of asample of capsules 
      
Is the sample examined free of 
empty capsules? 
      
2.9 Smell       
Does the medicine smell the same 
as the original 
(If available)? 
Does it smell peculiar? 
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Appendix 4: Questionnaire format for manufacturer for authenticity investigation 
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Appendix 6: Questionnaire format for MRAs for authenticity investigation of 
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Appendix 7: E-mail format for importing country for registration verification of 
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Appendix 8: Questionnaire format for importing country for registration 
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Appendix 9:  Quantity & content uniformity test results of omeprazole collected 
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Appendix 10:  Quantity & content uniformity test results of omeprazole collected 
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Appendix 14:  Quantity and content uniformity test results of pioglitazone HCl 
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Appendix 16:  Dissolution test results of pioglitazone HCl collected from Myanmar 
in 2015 
2nd and 3rd stage 
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